1	
2	
3	
4	
5	MYOPIA TREATMENT STUDY
6	(MTS1)
7	
8	Low-Dose Atropine for Treatment of Myopia
9	
10	PROTOCOL
11	
12	Protocol Identifying Number: MTS1
13	IND Sponsor: Jaeb Center for Health Research, Inc.
14	Version Number: v5.1
15	April 6, 2020

16	PROTOCOL AMENDMENT IV (24 Mar 2020)
17	
18	This amendment provides for the following protocol changes:
19	
20	Protocol Change # 1
21	
22	Original Protocol
23	Office visits are conducted at 6, 12, and 18-months post-randomization.
24	
25	Protocol Change
26	A virtual visit may be completed at 6, 12, or 18-months in the event that an in-person office visit
27	cannot be completed by the participant. Data collected during a virtual visit are a subset of the
28	data that are collected at an in-office visit (summarized in section 4.9) that can be collected by
29	means of a phone call, or other smartphone or computer based video/audio method of
30	communication such as teleconferencing.
31	
32	Rationale for Change and Impact on Study Design
33	Due to the coronavirus (COVID-19) pandemic, participating clinical centers may be unable to
34	see research participants for in-office study visits in the coming months. The protocol is being
35	amended to allow for a virtual visit to be completed at 6, 12, or 18-months instead of an office
36	visit. Given that these visits are prior to the 24-month primary outcome visit, the overall
37	scientific integrity of the study is maintained.
38	
39	Effect of Change on Informed Consent Form and Study Participants
40	No changes are needed to the current informed consent or assent forms. The data collected by
41	virtual visit are a subset of the data that would be collected at an in-office visit already described
42 43	in the consent form.
43 44	Protocol Change # 2
44	Frotocol Change # 2
46	Original Protocol
40	Females who have experienced menarche will undergo a urine pregnancy test at each follow up
48	visit after randomization. Study medication will be discontinued if the test result is positive.
49	visit after fandomization. Study medication will be discontinued if the test result is positive.
50	Protocol Change
51	A pregnancy test will be performed at home if an office visit cannot be completed. Pregnancy
52	testing is being omitted at the 30-month visit which occurs 6 months after study medication has
53	been discontinued.
54	ocen discontinued.
55	Rationale for Change and Impact on Study Design
56	Female participants who have experienced menarche must not be pregnant to continue on study
57	medication. The protocol has been revised to require a pregnancy test to be performed at home
58	instead of in the office if an in-person office visit cannot be completed by the participant.
59	
60	Effect of Change on Informed Consent Form and Study Participants
61	No changes are needed to the current informed consent form as the form states that pregnancy
62	tests are required at 6, 12, and 18-months for females who have experienced menarche.
63	

64	PROTOCOL AMENDMENT III (25 Feb 2019)
65 66	This amendment provides for the following protocol changes:
67	
68	Protocol Change #1
69	
70	Original Protocol
71	Potential participants with systemic diseases, the specified eye abnormalities, or the inability to
72	perform study testing were not explicitly excluded from the study.
73	
74	Protocol Change
75	The following items have been added as exclusion criteria in section 2.2.:
76	• Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple
77	sclerosis, Grave's disease, myasthenia gravis, diabetes mellitus, Parkinson's disease)
78 70	• Existing ocular conditions (e.g., retinal disease, cataracts, ptosis) or
79 80	systemic/neurodevelopmental conditions (e.g., Down syndrome) which may influence
80 81	refractive development.
81	• Any condition that in the judgement of the investigator could potentially influence refractive development.
83	 Existing conditions that may affect the long-term health of the eye or require regular
84	pharmacologic treatment that may adversely interact with study medication (e.g., JIA,
85	glaucoma, diabetes mellitus, pre-diabetes).
86	 Inability to comprehend and/or perform any study-related clinical tests.
87	
88	Rationale for Change
89	The reasons for excluding certain diseases and/or conditions are specified in the criteria to aid
90	investigators in understanding the exclusions. The inability to comprehend and/or perform any
91	study-related clinical tests by a potential participant would prevent the study from collecting
92	necessary valid and complete data.
93	
94 05	Protocol Change #2
95 06	Original Protocol
96 97	Section 4.1 includes the following two statements:
98	 A central pharmacy will <i>compound</i> the atropine and placebo eyedrops based on a participant-
99	specific treatment group and will package them in identical single-use ampules to maintain
100	masking.
100	 The atropine eyedrops will consist of 0.01% atropine. The placebo eyedrops will consist of
101	0.5% hydroxypropol methylcellulose and 1:10,000 benzalkonium chloride.
102	0.5% hydroxypropor methyrcentriose and 1.10,000 benzarkonnum chloride.
103	
104	Protocol Change
105	A separate section 4.1 has been added to better describe Study Medication.
106	
107 108 109 110	Nevakar is manufacturing the study drug (0.01% atropine) and placebo and packaging both in identical-appearing single-use ampules. In addition to 0.01% atropine, the ampules contain a buffer similar to artificial tears while the placebo contains just the buffer similar to artificial tears. The atropine and placebo ampules are sent to a central pharmacy, which will label and

- 111 package multiple atropine or placebo ampules into three month supply packages to maintain
- 112 masking. The packages of ampules will be shipped to participating sites in insulated shipping
- boxes designed to maintain study drug at 59 to 77 degrees F during shipping. Participating sites
- 114 will store study drug at room temperature (between 68 and 77 degrees F) prior to dispensing
- 115 study medication packages to study participants. Additional study medication details are
- 116 summarized within a separate investigational product manual.
- 117
- 118 <u>Rationale for Change</u>
- 119 The terms "compound" and "1:10,000 benzalkonium chloride" were inadvertent holdovers from
- a previous draft protocol that was written when the study was expected to use a compounding
- 121 pharmacy to produce the atropine eyedrops. No compounding or preservative is needed for the
- study medication currently manufactured in single-use ampules (monitored by US FDA) which are shipped directly from the manufacturer.
- 123 124

125 **Protocol Change #3**

126

127 <u>Original Protocol</u>

- 128 Section 4.3 on phone calls stated that "Two weeks following randomization (±3 days), the site
- 129 will contact parents *to confirm receipt of study medication* and question the parent as to whether 130 the child is experiencing any issues with treatment."
- 131
- 132 Protocol Change
- 133 The phrase "to confirm receipt of study medication" has been omitted.
- 134
- 135 <u>Rationale for Change</u>
- 136 There is no need to confirm receipt of study medication on the 2-week phone call because study
- 137 medication is handed directly to participants at their office visit at the time of randomization.
- 138 The "to confirm receipt of study medication" wording was an inadvertent holdover from a
- 139 previous draft protocol which was written when the study was expected to mail study medication
- 140 to participants.
- 141

142 **Protocol Change #4**

- 143
- 144 <u>Original Protocol</u>
- 145 Although a negative urine pregnancy test is required for enrollment of any female who had
- 146 reached menarche, no pregnancy testing was described during follow up.
- 147
- 148 <u>Protocol Change</u>
- 149 A pregnancy test is now required at every post-randomization follow up visit for females who
- 150 have experienced menarche.
- 151
- 152 <u>Rationale for Change</u>
- 153 Pregnancy testing during post-randomization follow up (section 4.9) was felt necessary to
- 154 enforce the existing requirement that study medication be discontinued in the event of pregnancy
- 155 during the study.
- 156

157 **Protocol Change #5**

- 158
- 159 Original protocol

MTS1 Protocol V5.1 (06Apr2020)

- 160 One inclusion criteria for randomization was interocular difference <= 0.1 logMAR (<= 5 letters
- 161 by E-ETDRS testing).
- 162
- 163 Protocol change
- 164 This inclusion criteria has been changed to interocular difference $\leq 0.2 \log MAR$ (≤ 10 letters
- 165 by E-ETDRS testing) in sections 1.11, 1.12, and 3.4.
- 166
- 167 Rationale for Change
- 168 The intent of the exclusion criteria for interocular difference was to exclude children with
- amblyopia; however, the previous interocular difference of 0.1 (5 letters) is within test-retest
- 170 variability for E-ETDRS visual acuity testing. The criteria was expanded to allow enrollment of
- 171 children with interocular differences up to 0.2 logMAR (10 letters), the threshold that is used to
- 172 define amblyopia in several other PEDIG studies of intermittent exotropia.
- 173
- 174
- 175

176	PROTOCOL AMENDMENT II (12 Jun 2018)
177 178	This amendment provides for the following protocol changes:
179 180	Protocol Change #1
181	Original Protocol
182 183 184 185 186 187	<u>Original Protocol</u> It was not an inclusion criterion that participants were required to have excellent compliance with spectacle correction either to be enrolled into the run-in phase or to be eligible for randomization. Participants who were not currently wearing refractive correction were eligible for the study and could have spectacle correction initiated during the run-in phase.
187	Protocol Change
189 190 191 192 193 194	Excellent compliance with refractive correction (76% to 100% of waking hours) for at least one month will be an eligibility criterion for enrollment into the run-in phase (sections 1.11, 1.12, and 2.2). Similarly, excellent compliance with refractive correction during the run-in phase will be encouraged and will be required to be eligible for randomization (sections 1.11, 1.12, 2.5, 2.6, 3.2, 3.3, and 3.4).
195	Rationale for Change
196 197 198 199 200 201 202	It is not known whether spectacle compliance could interact with the effect of atropine eyedrops, but limiting the study to children who are compliant with refractive correction will guard against the possibility of having lowered statistical power for analysis should such an interaction exist. It was also felt that children who are compliant with refractive spectacle correction might also be more likely to be compliant with nightly eyedrops for two years than children who are not compliant with refractive correction. It is acknowledged that the study results will be generalizable only to children who are compliant with refractive correction.
203 204	Protocol Change #2
204	
206 207 208 209 210	<u>Original Protocol</u> The original protocol indicated that "It is the investigators' opinion that the protocol's level of risk falls under DHHS 46.404, which is research not involving greater than minimal risk." (section 6.4.3)
210 211 212	<u>Protocol Change</u> The revised protocol states that "The Jaeb Center Institutional Review Board has classified the
213 214 215	protocol as research involving greater than minimal risk using the federal definition under 45 CFR 46.102i."
216 217 218 219	<u>Rationale for Change</u> The protocol was assigned the risk level of "research involving greater than minimal risk" by the Jaeb Center for Health Research Institutional Review Board when it approved the protocol.
220	Protocol Change #3
221	Original Protocol

222	Mean corneal	radius was o	ne of the	biometric	parameters to	be measured.	Three summary
					1		J

- 223 measurements of axial length, mean corneal radius, anterior chamber depth and lens thickness
- 224 were to be taken using an optical biometer (e.g. IOLMaster, LENSTAR).
- 225

226 Protocol Change

- 227 Flat corneal radius will be measured instead of mean corneal radius because that is what both optical
- biometers can measure. The first summary measurement of axial length, flat corneal radius, anterior chamber depth and lens thickness will be collected, with each value based on the individual
- chamber depth and lens thickness will be collected, with each value based on the individual instrument's method of taking and then averaging multiple measures
- instrument's method of taking and then averaging multiple measures.
- 232 Rationale for Change
- For corneal curvature, the only common measurement and unit of measure for the two optical biometers being used is flat corneal radius and diopter. To avoid increasing the testing burden
- for participants, a single measurement was deemed sufficient for these four biometricparameters.
- 230 237
- In addition, the following minor corrections/clarifications have been made.
- Typos were corrected in protocol change #1 in protocol amendment I and in section 7.4.2 to reflect that near visual acuity is measured binocularly, not in each eye.
- Clarification that the *average* spherical equivalent between eyes is used for the primary analysis of myopia progression (section 1.1)
- In section 3.4 concerning eligibility for randomization, clarified that participants who do not meet eligibility criteria will be withdrawn from the study *without being randomized*.
- Clarified in section 6.4.2 that it refers to the 24-month primary outcome in the section
 pertaining to participants develops adverse effects serious enough to discontinue study
 medication.
- The enrollment visit has been added to the list of visits that are paid for by the study (section 5.4); it was originally omitted in error.
- In section 7.1.1 regarding the 24-month on-treatment primary analysis
- Clarified that adjustment covariates are included to improve power for the treatment
 group comparison, as well as to account for potential residual confounding
 Clarified that baseline spherical equivalent refractive error (SER) will be included in the
 analysis model as an adjustment factor, while the change in SER at all follow-up visits
 up to and including the 24-month visit will be included in the longitudinal outcome
 vector. Further details, including handling of missing data, will be included in the
 separate Statistical Analysis Plan.
- Section 7.6 has been updated based on recent decision from the Data Safety and Monitoring
 Committee that evaluation of whether an interim monitoring is needed would be made after 6
 months of recruitment and before any outcome data are reviewed.
- 268

264

252

269 In Section 6.4.2, clarified that the reason for trying progressive lenses is to address adverse • 270 events related to near focusing problems. 271 272 In the statistical analysis chapter, a few minor corrections have been made to the data for two 273 previous studies (CLEERE and ATOM2) that are cited as background data for estimating sample size (sections 7.8.2. 7.8.3). Note that none of these minor changes affected the sample 274 275 size calculation. 276 277 In section 7.8.5, a few minor corrections have been made to the numbers in Table 2 on the • 278 expected width of confidence intervals on the treatment group comparisons of myopia 279 progression in racial subgroups. None of these minor changes were substantive. 280 281 In section 7.8.1, the purpose of the general considerations for sample size section was • 282 clarified. In addition, two sentences were omitted here as they were already covered 283 elsewhere in section 7.8. 284 285 • In section 2.4, some details of the cycloplegic autorefraction and other biometry 286 measurements have been omitted and moved to a separate manual of procedures. 287

	PROTOCOL AMENDMENT I (11 Dec 2017)
Thi	is amendment provides for the following protocol change:
Pro	otocol Change #1
Ori	ginal Protocol
Bin	ocular near visual acuity will be assessed at the 6-month visit only. The analysis plan sisted of tabulating 6-month binocular near visual acuity by treatment group.
Pro	tocol Change
(sec	ocular near visual acuity will be assessed at both the Randomization visit and the 6-month visit etion 3.2). The analysis plan was changed to calculate the proportion of participants with loss o t corrected near vision >1 logMAR line at 6 months (sections 1.1, 1.12, and 7.4.2).
Rat	ionale for Change
Bin In c	ocular near visual acuity is an important outcome to assess the safety of low-dose atropine. order to interpret any change in binocular near visual acuity between randomization to six nths, a baseline measure is needed at the time of randomization.
Pro	otocol Change #2
Ori	ginal Protocol
	e eye drop questionnaire will be completed at each follow up visit.
Pro	tocol Change
The	e eye drop questionnaire will be completed at each follow up visit except the 30-month visit etions 1.1.1, 1.12, 4.8, and 7.4.1).
Rat	ionale for Change
The	e eye drop questionnaire is not relevant to the 30-month visit as eye drops are to be continued at the 24-month visit.
Pro	otocol Change #3
Ori	ginal Protocol
	e criterion for a serious adverse event did not include a congenital anomaly/birth defect.
Pro	tocol Change
	e criterion for a serious adverse event now includes a congenital anomaly/birth defect (section
	ionale for Change
	ngenital anomalies and birth defects are part of the Food and Drug Administration definition a serious adverse event.

KEY ROLES

JCHR Coordinating Center Director					
Name, degree	Raymond Kraker, M.S.P.H.				
Title	Director, PEDIG Coordinating Center				
Institution Name	Jaeb Center for Health Research 15310 Amberly Drive, Suite 350 Tampa, FL 33647 Phone: 1-888-797-3344 Fax: 1-888-697-3344 Email: <u>rkraker@jaeb.org</u> http://www.pedig.net				
JCHR Principal Investigator					
Name, degree	Danielle Chandler, M.S.P.H.				
Title	Principal Investigator				
Institution Name	Jaeb Center for Health Research 15310 Amberly Drive, Suite 350 Tampa, FL 33647 Phone: 1-888-797-3344 Fax: 1-888-697-3344 Email: <u>dchandler@jaeb.org</u> http://www.pedig.net				
Protocol Co-Chair					
Name, degree	Michael X. Repka, M.D.				
Title	Protocol Co-Chair				
Institution Name	Wilmer Eye Institute 233 Wilmer Institute, 600 N Wolfe St Baltimore, MD 21287 Phone: (410) 955-8314 Fax: (410) 955-0809 Email: <u>mrepka@jhmi.edu</u>				
Protocol Co-Chair					
Name, degree	Katherine K. Weise, O.D.				
Title	Protocol Co-Chair				
Institution Name	University of Alabama at Birmingham School of Optometry 1720 2 nd Ave South Birmingham, AL 35294 Phone: (205) 934-2933 Fax: (205) 934-6758 Email: kweise@uab.edu				
Medical Monitor					
Name, degree	Roy W. Beck, M.D., Ph.D.				
Title	Director, Jaeb Center for Health Research				
Institution Name	Jaeb Center for Health Research 15310 Amberly Drive, Suite 350 Tampa, FL 33647 Phone: 1-888-797-3344 Fax: 1-888-697-3344				

337		TABLE OF CONTENTS	
338			
339		LES	
340		ABBREVIATIONS	
341		R 1: BACKGROUND AND SUMMARY	
342	1.1	Epidemiology and Clinical Characteristics:	
343	1.2	Retardation of Myopia Progression:	
344	1.3	Atropine Treatment:	
345	1.4	Previous Randomized Trials of Atropine Treatment to Reduce Myopia Progression:	
346	1.5	Persistence of Atropine Effect:	
347	1.6	Atropine and Race:	
348	1.7	Safety of Atropine Treatment:	
349	1.8	Why is Another RCT Needed?	
350	1.9	Public Health Importance	
351	1.10	Study Objectives	
352	1.11	Synopsis of Study Design	
353	1.12	Study Flow Chart	
354 355		CR 2: ENROLLMENT	
	2.1	Eligibility Assessment and Informed Consent/Assent	
356	2.2	Eligibility Criteria for Enrollment into Run-in Phase	
357 358	2.3 2.4	Historical Information	
359	2.4 2.5	Testing at the Enrollment/Run-in Visit Refractive Correction	
360	2.5 2.6		
361		Treatment in Run-In Phase	
362	3.1	A S: KANDOWIZATION Assessment of Compliance with Artificial Tears	
363	3.1	Assessment of Compliance with Refractive Correction	
364	3.2	Testing at the Randomization Visit	
365	3.3	Confirmation of Eligibility for Randomization	
366	3.5	Randomization.	
367		RANGOMIZATION R 4: TREATMENT AND FOLLOW-UP IN RANDOMIZED TRIAL	
368	4.1	Study Medication.	
369	4.2	Treatment 0 to 24 Months	
370	4.3	Telephone Calls	
371	4.4	Masking of Treatment Group	
372	4.5	Compliance with Study Treatment	
373	4.6	Off-Treatment Phase >24 to 30 Months	
374	4.7	Side Effects of Treatment	
375	4.8	Follow-up Visit Schedule in Randomized Trial	
376	4.9	Follow-up Visit Testing Procedures	
377	4.10	Management of Refractive Error	
378	4.11	Non-Randomized Treatment Other than Refractive Correction	
379	4.12	General Considerations	
380	СНАРТЕ	R 5: MISCELLANEOUS CONSIDERATIONS IN FOLLOW-UP	
381	5.1	Participant Withdrawals	5-1
382	5.2	Discontinuation of Study	5-1
383	5.3	Travel Reimbursement	5-1
384	5.4	Costs Covered by the Study	5-1
385	5.5	Costs Not Covered by the Study	
386	СНАРТЕ	R 6: ADVERSE EVENTS AND RISKS	
387	6.1	Recording of Adverse Events	
388	6.2	Reporting Serious or Unexpected Adverse Events	
389	6.3	Data and Safety Monitoring Committee Review of Adverse Events	
390	6.4	Risks	
391	6.4.		
392	6.4.2		
393	6.4.		
394	СНАРТЕ	R 7: SAMPLE SIZE ESTIMATION AND STATISTICAL ANALYSIS	7-1

395	7.1	Primary Objective: Efficacy on Atropine Treatment (24 Months)	
396	7.1.1	Primary Analysis - Refractive Error at 24 Months (On-Treatment)	
397	7.1	.1.1 Sensitivity Analyses	
398	7.1.2	Secondary Outcomes at 24 Months (On-Treatment)	
399	7.1	.2.1 Proportion of Participants with Progression >=2D at 24 Months	
400	7.1	.2.2 Change in Axial Length at 12 and 24 Months	
401	7.1	.2.3 Compliance	
402	7.1.3	Secondary Outcomes at 12 Months (On-Treatment)	
403	7.1	.3.1 Refractive Error at 12 Months	
404	7.1	.3.2 Proportion of Participants with Progression >=1D at 12 Months	
405	7.2	Secondary Objective: Efficacy off Atropine Treatment (30 Months)	
406	7.3	Additional Analyses	
407	7.3.1	Treatment Effect in Subgroups	
408	7.3.2	Treatment Effect over Time	
409	7.3.3	Exploratory Analyses of Additional Ocular Biometric Parameters	
410	7.4	Safety Analyses	
411	7.4.1	Adverse Effects of Eye Drops	
412	7.4.2	Visual Acuity	
413	7.5	Need for Bifocals	
414	7.6	Interim Analysis	
415	7.7	Data Tabulations and Other Analyses	
416	7.8	Sample Size	
417	7.8.1	General Considerations	
418	7.8.2	Sample Size for Primary Objective: Efficacy on Atropine Treatment	
419	7.8.3	Sample Size for Secondary Objective: Efficacy off Atropine Treatment	
420	7.8.4	Summary of Sample Size Estimation	
421	7.8.5	Precision within Racial Subgroups	
422	CHAPTER	8 8: DATA COLLECTION AND MONITORING	
423	8.1	Case Report Forms and Device Data	
424	8.2	Study Records Retention	
425	8.3	Quality Assurance and Monitoring	
426	8.4	Protocol Deviations	
427		R 9: ETHICS/PROTECTION OF HUMAN PARTICIPANTS	
428	9.1	Ethical Standard	
429	9.2	Institutional Review Boards	
430	9.3	Informed Consent Process	
431	9.3.1	Consent Procedures and Documentation	
432	9.3.2	Participant and Data Confidentiality	
433	CHAPTEF	R 10: REFERENCES	
434			

LIST OF ABBREVIATIONS

435

430	5
-----	---

ABBREVIATION	DEFINITION			
ANCOVA	Analysis of Covariance			
ATOM	Atropine for the Treatment of Childhood Myopia Study			
CFR	Code of Federal Regulations			
CI	Confidence Interval			
CLEERE	Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error			
CRF	Case Report Form			
DSMC	Data Safety and Monitoring Committee			
FDA	Food and Drug Administration			
GCP	Good Clinical Practice			
ICH	International Council for Harmonisation			
IRB	Institutional Review Board			
MCMC	Monte Carlo Markov Chain			
PI	Principle Investigator			
PEDIG	Pediatric Eye Disease Investigator Group			
QA	Quality Assurance			
QC	Quality Control			
RBM	Risk Based Monitoring			
SE	Spherical equivalent			
SER	Spherical equivalent refractive error			
SVL	Single vision lenses			

Chapter 1: BACKGROUND AND SUMMARY

440 This study is being conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and

funded through a cooperative agreement from the National Eye Institute of the NationalInstitutes of Health.

443

444 **1.1 Epidemiology and Clinical Characteristics:**

Myopia is one of the most commonly occurring ocular disorders, with an estimated prevalence of 13% to 49% in adult population-based studies.^{1, 2} In children, the prevalence of myopia in population-based studies worldwide ranges from 1.2% to 59.1%,^{1, 3, 4} with variations due to age and race and definition used to classify myopia. In the US, in children 6-72 months of age, prevalence has been reported at 0.7 -1.2% in Non-Hispanic white children,^{5, 6} 3.98% in Asian children,⁶ 5.5-6.6% in African American children^{5, 7} and 3.7% in Hispanic children.⁷ Not only is the prevalence of myopia in adults relatively high, but it is increasing in the US⁸

452 (<u>http://www.nei.nih.gov/eyedata/myopia.asp#4</u>) and around the world.⁹

453

454 Progression of myopia primarily occurs due to elongation of the axial length of the eye. The

455 average increase in myopia has been estimated at 0.5 diopters per year (personal communication

456 with the Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE)

457 study group between November 2015 and April 2016).¹⁰⁻¹² Retarding progression of myopia has

been the focus of much research, since high levels of myopia (>-6.00D) are associated with

retinal and vitreous detachment, myopic macular degeneration, and increased risk of glaucoma and cataract.^{13, 14} A recent report for the US Population estimated the prevalence of high myopia

460 and cataract.^{13, 14} A recent report for the US Population estimated the prevalence of high myopia 461 and myopic choroidal neovascularization to be 3.92% (95% confidence interval [CI], 2.82-5.60)

462 and 0.017% (95% CI, 0.010-0.030), respectively, among adults in the United States aged 18

463 years and older in 2014.¹⁵ This translated into a population burden of approximately 9 614 719
 464 adults with high myopia, and 41 111 adults with myopic choroidal neovascularization.

465

466 **1.2 Retardation of Myopia Progression:**

467 Treatment to retard myopia progression is important for preventing the development of high 468 myopia and associated sequelae. Various management approaches have been reported, with

469 varying success, including the use of anti-muscarinic pharmacological agents (atropine,

470 pirenzepine, cyclopentolate), bifocals, progressive additional lenses, contact lenses, contact

471 lenses with peripheral myopic defocus, under-correction or part-time optical correction, and

472 orthokeratology.^{16,17} Some studies have found that an increase in the amount of time spent

473 outdoors may have a protective effect on the progression of myopia.¹⁸⁻²⁰ In a recent Cochrane

474 Systematic Review entitled Interventions to Slow Progression of Myopia in Children,¹⁶ anti-

475 muscarinic pharmacological treatments were found to be more effective than other treatments.
476 Nevertheless, side-effects from mydriasis and cycloplegia with atropine 1% were significant.

476 Nevertheless, side-effects from inydrasis and cycloplegia with adoptie 176 were significant. 477 More conclusive evidence is needed regarding optimal dose (i.e., dose with meaningful treatment

478 effect with minimal side-effects), lasting effects of treatment, and efficacy of anti-muscarinic

479 pharmacological treatments combined with other treatment modalities, such as bifocals.¹⁶

480481 **1.3** Atropine Treatment:

482 Use of topical atropine for treatment of myopia has been advocated since the 1800s.²¹

483 Summarizing a wealth of knowledge on atropine treatment for reduction of myopia progression,

- 484 1% atropine daily with or without multi-focal spectacles is most commonly used, resulting in an
- 485 average reduction of myopia progression of 90%.²² The mechanism by which atropine slows
- 486 myopia progression is largely unknown, but has been hypothesized to occur via elimination of
- 487 accommodation, local retinal effects that slow progression, or potential biochemical changes
- 488 brought about through binding of atropine with the muscarinic receptors.¹⁶ Another possible
- 489 mechanism of slowing myopic progression with atropine may be via increased UVA exposure²³ 490 as a result of a dilated pupil, which exposure has been shown to strengthen the sclera via
- 490 as a result of a dilated pupil, which exposure has been shown to strengthen the sclera via
 491 crosslinking of scleral collagen,²⁴ potentially limiting axial lengthening. Although this last
- 491 crossmiking of science conagen, potentiarly minuing axial rengineming. Although this last 492 mechanism is somewhat speculative, the general impression from the literature is that, regardless
- 492 of mechanism, 1% atropine appears to be very effective.
- 494

495 **1.4 Previous Randomized Trials of Atropine Treatment to Reduce Myopia Progression:**

496 Several randomized trials of prevention of myopia progression using atropine have been497 conducted in recent years.

- Yen and colleagues²⁵ in 1989 compared one year of 1% atropine every other night, 1% cyclopentolate every night, and normal saline every night in 96 children aged 6 to 14 years with myopia ranging from -0.50D to -4.00D. Children in the atropine group had a mean myopia progression over 1 year of -0.219D, whereas children receiving cyclopentolate progressed -0.578D and children receiving normal saline progressed 0.914D.
- In 1999, Shih and colleagues²⁶ reported a study of 200 children aged 6 to 13 years with myopia ranging from -0.50D to -6.75D that compared 0.5%, 0.25%, and 0.1% atropine to 5% tropicamide. Children received atropine or tropicamide eyedrops nightly for up to 2 years. At the end of 2 years, all atropine-treatment groups had less myopia progression (-0.04±0.63 D/year, -0.45±0.55D/year, and -0.47± 0.91D/year, respectively) than the tropicamide group (-1.06±0.61D/year).
- 510 Subsequently, Shih and colleagues²⁷ studied the effect of multi-focal glasses with and without atropine to control progression of myopia. The study randomized 227 children to 511 512 18 months of 0.5% atropine + multifocal lenses, multi-focal lenses alone, or single vision glasses. Myopia progressed only -0.42D±0.07D with atropine + multi-focal lenses 513 514 compared with -1.19D±0.07D with multi-focal lenses and -1.40D±0.09D with single 515 vision lenses, leading the authors to conclude that atropine treatment is effective for 516 slowing the progression of myopia and may act via a mechanism of accommodation 517 inhibition.
- 518 More recently, the Atropine for the Treatment of Childhood Myopia (ATOM) study was 519 a RCT comparing nightly administration of 1% atropine to vehicle (0.5% hydroxypropyl 520 methylcellulose and 1:10,000 benzalkonium chloride) over 2 years in 400 children ages 6 521 to 12 years with myopia ranging from -1.00D to -6.00D.²⁸ Only one eye of each child 522 was chosen for treatment. After 2 years, myopia in children receiving 1% atropine had 523 progressed -0.28D±0.92D versus -1.20D±0.69D in the placebo-treated eye (Figure 1). 524 Axial length was also reduced in atropine-treated eyes compared with placebo-treated eyes (-0.02±0.35mm vs 0.38±0.38mm). 525
- The ATOM2 study²⁹ compared 3 doses of atropine (0.5%, 0.1% and 0.01%) in 400
 children with myopia of at least -2.00D and found 2-year myopia progression of 0.30±0.60D, -0.38±60D, and -0.49±0.63D respectively (Figure 1). Although there was no
 control group, myopia progression was significantly lower than that observed in controls

- in ATOM1 (-1.20D±0.69D), but was not different from the 1% atropine-treated cohort (0.28D±0.92D). Axial length growth was lower in both 0.5% and 0.1% groups compared
- 532 with the 0.01% group (0.27 ± 0.25 mm, 0.28 ± 0.27 mm, and 0.41 ± 0.32 mm respectively, 533 P<0.001).
- 534
- 535 The effect of treatment on myopia progression and axial length in these randomized trials is
- 536 compiled in Table 1. Although there were good overall results with atropine treatment, a logistic
- regression analysis of ATOM1 data suggested that there is a subgroup of participants (younger
- 538 participants with higher levels of myopia and trending towards progression) whose myopia
- 539 progressed significantly despite atropine treatment.³⁰

Study	Ethni- city	Treatment Group **	Ν	Time point	Change in Myopia (D)	Change in Axial Length (mm)	Comments			
		Control (saline)	32	1 yr	-0.914 ± 0.581	not reported				
Yen ²⁵	Asian	Atropine 1%***	32	1 yr	-0.219 ± 0.538	not reported	Only about 40% (96/247) of randomized participants included in analysis. Excluded participants with less than 100% compliance.			
		Cyclopentolate 1%	32	1 yr	-0.578 ± 0.490	not reported				
		Atropine 0.5%	41	≤2 yr	-0.04 ± 0.63	not reported				
C1 :1 26		Atropine 0.25%	47	≤2 yr	-0.45 ± 0.55	not reported	Likely confounded by refractive correction as "suggested" bifocals in atropine 0.5%, under-correction in atropine 0.25, and full correction			
Shih ²⁶	Asian	Atropine 0.1%	49	≤2 yr	-0.47 ± 0.91	not reported	in atropine 0.1%. Outcomes by cycloplegic autorefraction. Length o treatment/follow-up not well defined.			
		Tropicamide	49	≤2 yr	-1.06 ± 0.61	not reported	- treatment/fonow-up not wen defined.			
		Control (SVL)****	61	1.5 yr	-1.40 ± 0.09	0.59 ± 0.04				
Shih ²⁷	Asian	Multifocal lenses	66	1.5 yr	-1.19 ± 0.07	0.49 ± 0.03	Double blind randomization.			
Shill	Tistuit	Atropine 0.5% + multifocal lenses	61	1.5 yr	-0.42 ± 0.07	0.22 ± 0.03				
	28 Asian				G ()	NR	1 yr	-0.76 ± 0.44	0.20 ± 0.30	
ATOM ²⁸			. Control	190	2 yr	-1.20 ± 0.69	0.38 ± 0.38	Outcomes by masked cycloplegic autorefraction.		
ATOM ²⁰		Asıan -	Asian	Asian	1. 10/	NR	1 yr	0.03 ± 0.50	-0.14 ± 0.28	Number of participants analyzed at 1yr not specified but suspect similar to number analyzed at 2yrs.
				Atropine 1%	166	2 yr	-0.28 ± 0.92	-0.02 ±0.35	- similar to number analyzed at 2915.	
			NR	1 yr	-0.17 ± 0.47	0.11 ± 0.17				
		Atropine 0.5%	139	2 yr	-0.30 ± 0.60	0.27 ± 0.25	Outcomes by cycloplegic autorefraction, but no control group.			
1 70 1020			NR	1 yr	-0.31± 0.50	0.13 ± 0.18	Number of participants analyzed at 1yr not specified but suspect			
ATOM2 ²⁹	Asian	Atropine 0.1%	141	2 yr	-0.38 ± 0.60	0.28 ± 0.27	similar to number analyzed at 2yrs.			
		А		NR	1 yr	-0.43 ± 0.52	0.24 ± 0.19			
			Atropine 0.01%	75	2 yr	-0.49 ± 0.60	0.41 ± 0.32			
		Atropine 0.01%	17	5 yr	-2.25 ± 1.11	$1.21\pm\ 0.54$				
ATOM2 ³¹	Asian	Atropine 0.1%	82	5 yr	-2.34 ± 1.07	1.08 ± 0.53	Children progressing more than 0.50 D during washout year three were started back on atropine 0.01% for two additional years.			
		Atropine 0.5%	93	5 yr	-2.32 ± 1.04	1.03 ± 0.47	and a second of a second of the test of a second for yours.			

540 Table 1: Summary of Randomized Trials Evaluating Effect of Atropine on Myopia Progression

541 542 *N = number with outcome data. NR = not reported. **Daily treatment unless otherwise noted ***Treatment every other day. ****SVL = single vision lenses

MTS1 Protocol V5.1 (06Apr2020)

1-4

43 Figure 1: Summary of Findings from ATOM²⁸ and ATOM2²⁹ Studies*

543 544 545




Figure 6. Summary of findings from the ATOM1 and ATOM2 studies: change in spherical equivalent (SE). ATOM = Atropine for the Treatment of Myopia; D = diopter.

49 *Figure reproduced from Chia et al, 2016.³¹

MTS1 Protocol V5.1 (06Apr2020)

1-5

551 **1.5 Persistence of Atropine Effect:**

552 Following cessation of atropine treatment, there appears to be a rebound of myopia progression, although the rate of myopia progression differs between studies and depending on which dose of 553 554 atropine was used. In a prospective long-term study, Brodstein and colleagues³² followed 253 555 children treated with atropine for up to 9 years. They found a rebound in myopia progression, 556 but the rate was no higher than observed in control participants. In a retrospective population-557 based study of atropine treatment for myopia, 214 children in Olmsted County, MN were 558 followed for a mean of 11.7 years, along with age-matched controls. Final refraction data at age 559 20 years indicated that benefits of atropine treatment remain after atropine treatment was 560 discontinued. Nevertheless, length of treatment and follow-up was not standardized in this 561 retrospective study. In the ATOM1 study, children were followed off atropine treatment, and myopia progression was reported after 1 year.³³ A higher rate of myopia progression in atropine-562 treated eyes following cessation of atropine compared with control fellow eyes was reported (-563 564 1.14±0.80D vs -0.38±0.39D in 1 year) (Figure 1). However, overall myopia remained less severe in atropine-treated eyes at the end of 3 years. In the subsequent ATOM2 study,³⁴ 356 of the 400 565 children enrolled in ATOM2 were followed for an additional year after stopping atropine. 566 Myopia progression off atropine was greatest following treatment with 0.5% atropine (-567 568 $0.87\pm0.52D$), with less progression off treatment with 0.1% (-0.68±0.45D) and 0.01% (-569 0.28±0.33D), leading to the conclusion that the effect of 0.01% atropine is more sustained 570 following treatment than with higher doses (Figure 1). The 0.01% atropine was restarted in a 571 subgroup that progressed more than 0.5 D in the washout year (year 3) for two additional years. 572 The resumption of atropine 0.01% treatment showed a lower progression in the subgroup treated 573 initially with atropine 0.01%, compared with higher doses in the first phase of the study (years 574 one and two).³¹

575

576 **1.6 Atropine and Race:**

Early in the 1900's, differences in dilation response to mydriatic drugs (although not specifically 577 578 atropine) were reported between different races, with African American and Asian participants requiring a longer time for mydriasis than White participants.³⁵ This phenomenon has become a 579 common clinical experience and has been reproduced by the works of others.³⁶ Work by Salazar 580 581 et al explored the mechanism by which this racial difference may occur, reporting that atropine is 582 rapidly taken up by melanocytes and released over time, leading to a longer time required to achieve mydriasis and a prolonged mydriatic effect in heavily-pigmented eyes as atropine is 583 released over an extended period of time.³⁷ In a meta-analysis of atropine for slowing 584 progression of myopia, Li et al³⁸ report that atropine slows the progression of myopia more in 585 586 Asian populations of children than it does for populations of white children, but note that 587 comparisons are limited by the lack of studies in non-Asian populations. They conclude that 588 further studies to determine ethnic differences in the effect of atropine for slowing the 589 progression of myopia are needed.

590

591 **1.7 Safety of Atropine Treatment:**

592 Atropine use is associated with photophobia, mydriasis, accommodative paralysis, and allergic or

593 hypersensitivity reactions. In an effort to reduce these side effects, Shih et al^{26} used 3 lower

doses of atropine than the commonly used 1% concentration (i.e., 0.5%, 0.25%, 0.1%), reporting

- that 0.25% and 0.1% atropine were well-tolerated throughout their 2-year study (no systemic or
- 596 ocular complications identified). The ATOM2 study also tested lower concentrations of atropine

597 (0.5%, 0.1%, and 0.01%), reporting that allergic conjunctivitis and dermatitis occurred in the

598 0.5% and 0.1% groups, but were absent in the 0.01% group, which only reported 1 case of near

- blur and 1 case of irritation.²⁹ The authors reported that 7% of children receiving atropine 0.01%
- requested glasses for blur or for photosensitivity in years one and two. In the further extension
- study to 5 years, no child required glasses for blur at near or for photosensitivity.³¹ Cooper at al³⁹
- 602 conducted a study to determine the maximal dose of atropine that is not associated with clinical
- 603 symptoms associated with higher doses, reporting that a dose of 0.02% atropine is the maximum
- 604 effective dose without clinical signs or symptoms. A recent study in 14 white university students
- found atropine 0.01% to be well tolerated.⁴⁰
- 606
- 607 Below (Table 2) is a summary of side effects reported with various doses of atropine for the
- 608 treatment of myopia progression in children.
- 609

Study	Ethnicity / Eye Color	Study Type*	N**	Dose***	Side effects
Yen 1989 ²⁵	Asian	Pro	32	1% ****	All experienced photophobia. No systemic or ocular complications reported.
Kennedy 2000 ⁴¹	Minnesota mainly white	Retro	214	1%	Photophobia (40.2%), Blurred vision (10.7%), Ocular allergic reaction (3.7%), Ocular discomfort (3.7%), Headache (2.3%), Bad taste in mouth (2.3%), Dry mouth (1.9%), Dry eyes (1.4%), Psychological problems (0.5%), Dizziness (0.5%)
ATOM1 (Chua 2006) 28	Asian	Pro	200	1%	No serious adverse events. Study withdrawals due to allergic or hypersensitivity reaction (4.5%), glare (1.5%), and blurred vision (1%)
ATOM1 recovery (Tong 2009) ³³	Asian	Pro	158	1%	Small decrease in best-corrected visual acuity from baseline, but ≤3 letters in all participants (occurred in controls as well). No reduction in near visual acuity compared with controls. No lens opacities.
Shih 1999 ²⁶	Asian	Pro	41	0.5%	0.5%: light sensitivity persisting >3 months in 22%, 2 children with intolerable photophobia, 2 children with fear of long-term effects, 1 child with recurrent blepharitis.
			47	0.25%	0.25%: light sensitivity >4 weeks in 7%. No systemic or ocular complications.
			49	0.1%	0.1%: No light sensitivity beyond 4 weeks. No systemic or ocular complications.
ATOM2 (Chia 2012) ²⁹	Asian	Pro	139	0.5%	0.5%: Reduced accommodation, impaired near visual acuity, and pupil size increased >3mm. Allergic conjunctivitis (6.2%). Serious adverse reactions (2%)
			141	0.1%	0.1%: Reduced accommodation, impaired near visual acuity, and pupil size increased >3mm. Allergic conjunctivitis (4.5%). Serious adverse reactions (2%)
			75	0.01%	0.01%: Serious adverse reactions (1%). Minimally reduced accommodation. No allergic conjunctivitis or dermatitis.
ATOM2 recovery (Chia	Asian	Pro	138	0.5%	0.5%: Accommodation reduced for 1 year after stopping (2 years administration). Near acuity reduced for an additional month.
2014)34			139	0.1%	0.1%: No effects after stopping
			71	0.01%	0.01%: No effects after stopping. 7% were given glasses for blur or photosensitivity ³¹
Wu 2011 ⁴²	Asian	Retro	97	0.05% for 6 months, then 0.1%	No reports of cataract or retinopathy noted during study period. Complaints of near blurring were "uncommon"
Cooper 2013 ³⁹	Brown iris U.S.	Pro	3	0.05%	0.05%: Accommodation deficits- no accommodation in 1 participant, 6D accommodation in 2 participants. 0.025%: borderline accommodation in 2 of 6 participants, clinically significant pupil dilation in 4 of 6 participants
	race not specified		6	0.025%	and minimal in 2 of 6. 0.0125%: 2 of 3 with subnormal accommodation (but no blurred vision).
1 200/43		D (3 21	0.012%	
Lee 2006 ⁴³ Fang 2010 ⁴⁴	Asian Asian	Retro Retro	21	0.05%	 33% had morning photophobia (1 into afternoon). 10% had hampered near vision. No irritation or allergic effects. 16% complained of photophobia with atropine vs 8% in control (p=0.4). No complaints of blurred vision. No systemic side effects.
Ekdawi 2015 (AAPOS Poster 2015) *Study type: Pro =	Mostly Caucasian	Retro	7	0.01%	1(14%) participant had headaches and discontinued treatment after 7 months. Participants (number not specified) had difficulty with reading in the first weeks that did not persist past 4-6 weeks with continued use.

610 Table 2. Side Effects/Safety of Atropine Treatment of Myopia

*Study type: Pro = prospective study Retro = retrospective study **N = number with outcome data. ***Treatment is daily unless otherwise noted ****Treatment is every other day.

MTS1 Protocol V5.1 (06Apr2020)

1-8

615 **1.8 Why is Another RCT Needed?**

- 616 To date, randomized trials of atropine for slowing the progression of myopia in children have
- 617 been primarily conducted on Asian populations. A meta-analysis comparing the effect of
- atropine on myopia progression in Asian and White children using data from both RCTs and
- 619 prospective cohort studies concluded that atropine may have a greater effect in Asian
- 620 populations.³⁸ A potential explanation of the observed differences of myopia progression
- between Asian and White children may be the mydriatic differences observed between highly
- 622 pigmented and lowly pigmented eyes in response to atropine.³⁵⁻³⁷ Although results of current
- RCTs are promising, additional studies in non-Asian populations are needed³⁸ to test the efficacy
- 624 of atropine in counteracting myopia progression, including dose studies.
- 625

626 **1.9 Public Health Importance**

627 The increasing prevalence of myopia and the unresolved problem of myopia progression pose

- 628 significant healthcare concerns. Increasing axial length and especially high levels of myopia (>-
- 629 6.00D) are associated with serious ocular co-morbidities, often resulting in visual impairment or
- 630 even blindness.⁴⁵ These include retinal detachment, myopic maculopathy, glaucoma and
- 631 cataract. While much research has considered the impact of preventing high myopia
- 632 development, there are relatively few participants who progress to those levels that would benefit
- 633 from reduction in progression. What is omitted from that discussion is the impact on reducing the
- 634 proportion of participants who progress even to moderate myopia. Many individuals would
- retain the ability to function without correction for some activities of daily living and not be
- 636 constantly dependent on vision correction. But far more important to this research is the
 637 recognition that there is a large number of individuals who progress to moderate myopia and
- 638 who by doing so are at increased risk for the same myopic complications compared with
- 639 emmetropic individuals. While the risk of each adverse impact from myopia is lower at lesser
- 640 amounts of myopia on an individual basis, the risk affects many more participants and thus
- slowing progression could protect more participants than from just preventing high myopia.
- 642
- Flitcroft has opined that it is important to slow progression even in the moderate range of -1.00
 to -6.00 D as those levels of myopia are also significantly associated with an increased risk of a
 range of ocular pathologies from glaucoma to retinal detachment⁴⁶ compared with emmetropia.
 Similarly, in the Blue Mountains Eye Study, the odds ratio for myopic maculopathy was 9.7
 when comparing myopia -3.00 to -4.99D with emmetropia.⁴⁷ Tideman et al found that the risk
- of visual impairment went up with increasing spherical myopia. They noted that the lifetime risk
- 649 at 75 years of age of was 3.0%.⁴⁵
- 650

651 Many existing treatments to slow the progression of myopia have proven either ineffective or

- unacceptable to the participant when administered for many years. Low-dose atropine treatmenthas the potential to reduce the prevalence of high myopia, reduce myopic progression among
- 654 children with moderate myopia, and thereby reduce the incidence of undesirable sequelae
- 655 associated with myopia.
- 656

657	1.10 Study Objectives
658	The objectives for this randomized trial are:
659	1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia
660	progression over a two-year treatment period in children aged 5 to less than 13 years with
661	myopia -1.00 to -6.00D at the time of enrollment (Primary Outcome On-Treatment).
662	 To determine the efficacy of atropine treatment on myopia progression 6 months
663	following cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment).
664	tonowing cessation of low-dose allopine treatment (Secondary Outcome Off-Treatment).
665	1.11 Synopsis of Study Design
666	The current study is designed as an efficacy study, making effort to maximize adherence to
667	treatment group assignments. After a run-in phase during which all participants are treated with
668	daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their
669	ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or
670	placebo for 24 months, followed by 6 months off treatment.
671	placebo for 24 months, followed by 6 months off treatment.
672	Major Eligibility Criteria for Run-in Phase (see section 2.2 for a complete listing)
673	 Age 5 years to <13 years at time of enrollment. Children within 4 weeks of their 13th
674	• Age 5 years to <15 years at time of enrollment. Children within 4 weeks of their 15 birthday are not eligible.
675	 Refractive error meeting the following by cycloplegic <i>autorefraction:</i>
676	 Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes
677	
678	
	1
679	• Currently wearing refractive correction (single vision eyeglasses or contact lenses)
680	• Excellent compliance with refractive correction (more than 75% of all waking hours) for
681	at least one month, based on investigator judgment after discussion with parent.
682	• No current or previous myopia treatment with atropine, pirenzepine or other anti-
683	muscarinic agent.
684	• No current or previous use of bifocals, progressive-addition lenses, or multi-focal contact
685	lenses.
686	• No current or previous use of orthoK, rigid gas permeable, or other contact lenses being
687	used to reduce myopia progression.
688	 No known atropine allergy.
689	
690	Additional Eligibility Criteria for Randomization
691	• Compliance with artificial tears at least 90% (days compliant/total days since receiving
692	study medication as evident by review of the compliance calendar and count of unused
693	ampules) during the run-in phase.
694	• Excellent compliance with refractive correction (more than 75% of all waking hours)
695	during run-in phase, based on investigator judgment after review of compliance calendars
696	and discussion with parent.
697	• Refractive correction in each eye (single vision eyeglasses or contact lenses with any
698	necessary adjustment for contact lens rotation and vertex distance) that meets the
699	following criteria:
700	• Myopia (by spherical equivalent) in both eyes must be corrected to within ± 0.50 D of
701	the investigator's cycloplegic measurement of refractive error.
702	• Cylinder power in both eyes must be within ± 0.50 D of the investigator's standard
703	refraction technique, which can be based on a cycloplegic or non-cycloplegic
704	refraction.

705	• Cylinder axis for both eyes must be within ± 5 degrees of the axis found on the
706	investigator's refraction when cylinder power is ≥ 1.00 D or within ± 15 degrees
707	when the cylinder power is <1.00 D.
708	Measurement of refractive error for assessing the above criteria may be performed as an
709	over-refraction or without refractive correction.
710	• Best-corrected distance visual acuity in current correction meeting the following criteria:
711	\circ 20/32 or better in each eye (>=76 letters by E-ETDRS testing)
712	• Interocular difference $\leq 0.2 \log MAR$ ($\leq 10 $ letters by E-ETDRS testing)
713	
714	Treatment Groups
715	Participants are randomly assigned 2:1 to the following two treatment groups:
716	• Atropine Group: 0.01% atropine eyedrops administered 1 drop to each eye daily in each
717	eye for 24 months, followed by 6 months off atropine eyedrops
718	• Placebo Group: Placebo eyedrops administered 1 drop to each eye daily in each eye for
719	24 months, followed by 6 months off placebo eyedrops
720	
721	Sample Size
722	Approximately 186 participants will be randomized in a 2:1 ratio to the two treatment groups
723	(\sim 124 in the atropine group and \sim 62 in the placebo group).
724	(12 millio di opinio group di di 02 millio pidecoo group).
725	Visit / Contact Schedule (timed from randomization unless otherwise specified)
726	Enrollment into run-in phase using daily artificial tear eyedrops for 2-4 weeks (and
727	glasses updated if required)
728	 Randomization Visit (2-4 weeks after enrollment)
729	 Phone Calls from site: after 2 weeks (± 3 days), and after 3, 9, 15, 21, and 27 months (+
729	• Finite Calls from site. after 2 weeks (\pm 5 days), and after 5, 9, 15, 21, and 27 months (\pm 1 month)
731	 Office Visits:
731	
732	
734	
734	
736	 24 months ± 4 weeks: Primary Outcome On-Treatment – discontinue treatment after visit
730	\circ 30 months ± 4 weeks: Secondary Outcome Off-Treatment– six months following
738	5° 50 months ± 4 weeks. Secondary Outcome OII-Treatment – six months following discontinuation of treatment
739	discontinuation of treatment
739	*A virtual visit may be completed at 6, 12, or 18-months if an in-person office visit cannot be completed
741	by the participant. If any safety events are identified during a virtual visit, participants will have
742	additional follow up as applicable.
743	
744	Testing Procedures
745	Cycloplegic autorefraction, axial length and additional biometry will be measured by a study
746	certified examiner at the enrollment visit and by a masked examiner at all follow up visits using
747	the same instrumentation on the participant throughout the study. Masking will be accomplished
748	by having site personnel administer cyclopentolate to both eyes of each participant before he/she
749	sees the masked examiner.
750	
751	At randomization and each follow-up exam except the 30-month visit, the effect of eyedrops will
752	be assessed with a questionnaire. Distance visual acuity will be assessed at randomization and

- the 30-month visit. Binocular near visual acuity will be assessed at randomization and the 6-
- 754 month visit.
- 755

756 Primary Analysis

- Treatment group comparison of change from baseline to 24 months in spherical
 equivalent (average of both eyes) as measured by a masked examiner using cycloplegic
- autorefraction (on-treatment comparison).

761 <u>Secondary Analysis</u>

- Treatment group comparison of change from baseline to 30 months in spherical
 equivalent (average of both eyes) as measured by a masked examiner using cycloplegic
 autorefraction (off-treatment comparison).
- 765

766 1.12 Study Flow Chart

ENROLLMENT INTO RUN-IN PHASE

Major Eligibility Criteria at Enrollment for Run-in Phase (see section 2.2 for a complete listing)

• Age 5 to <13 years of age at time of enrollment. Participants within 4-weeks of their 13th birthday are not eligible.

- Refractive error meeting the following by cycloplegic autorefraction:
 - Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes
 - \blacktriangleright Astigmatism <=1.50D in both eyes
 - Anisometropia <1.00D SE</p>
- Currently wearing refractive correction
- Excellent compliance with refractive correction (>75% of waking hours) for ≥ 1 month prior to enrollment
- No current or previous myopia treatment with atropine, pirenzepine or other anti-muscarinic agent
- No current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses
- No current or previous use of orthoK, rigid gas permeable, or other contact lenses to reduce myopia progression
- No known atropine allergy

Enrollment Exam Procedures

- Standard Refraction (with or without cycloplegia)
- Cycloplegic Autorefraction
- Cycloplegic Axial Length Measurement and Additional Biometry
- Prescribe refractive correction or change in refractive correction (if needed)
- Prescribe artificial tear eyedrops to be used one drop to each eye nightly for 2-4 weeks

RUN-IN PHASE (2-4 WEEKS)

- All participants are treated with daily artificial tear eyedrops
- Glasses are updated, if needed


RANDOMIZATION VISIT (2-4 WEEKS AFTER ENROLLMENT)


Additional Eligibility Criteria for Randomization

- Compliance with artificial tear eyedrops at least 90% during the run-in phase
- Excellent compliance with refractive correction (more than 75% of all waking hours) during the run-in phase
- Refractive correction in each eye (single vision eyeglasses or contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria:
 - Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D of the investigator's cycloplegic measurement of refractive error.
 - Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction.
 - Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D.</p>
- Best-corrected distance visual acuity in current correction meeting the following criteria:
 - \geq 20/32 or better in each eye (>=76 letters by E-ETDRS testing)
 - Interocular difference <= 0.2 logMAR (<= 10 letters by E-ETDRS testing)</p>

Testing Procedures

- Eye Drop Questionnaire
- Distance Visual Acuity Testing
- Binocular Near Visual Acuity
- Binocular Amplitude of Accommodation
- If > 4 weeks since enrollment into run-in phase, repeat cycloplegic autorefraction, axial length measurement and additional biometry





DISCONTINUE TREATMENT

- At the 24-month visit, study eye drops will be discontinued for both treatment groups
- No myopia treatment other than optical correction should be prescribed prior to the 30-month visit.



- Medical History
- Distance Visual Acuity Testing
- Binocular Amplitude of Accommodation
- Standard Refraction (with or without cycloplegia) (only if visual acuity ≥5 or more letters worse than baseline)
- Cycloplegic Autorefraction (masked)
- Cycloplegic Axial Length Measurement (masked) and Additional Biometry

780	Chapter 2: ENROLLMENT
781 782 783 784 785 786 786 787	2.1 Eligibility Assessment and Informed Consent/Assent The study plans to enroll a maximum of 400 participants into the Run-In Phase for whom informed consent is provided, such that approximately 186 participants will enter the Randomized Trial Phase. The number of participants randomized who self-report as East Asian ethnicity will be limited to no more than 25% of the overall sample (n=47 participants).
788 789 790 791 792 793 794 795 796	As the enrollment goal into the Randomized Trial Phase approaches 186 participants, sites will be notified of the end date for recruitment into the Run-In Phase. Participants whose parents have signed an informed consent form may be entered into the Run-in Phase until the end date, which means the expected number for the Randomized Trial Phase might be exceeded during the Run- in Phase. Enrollment into the Run-In Phase may be temporarily halted if necessary until it is determined how many participants in the Run-in Phase will enter the Randomized Trial Phase. The anticipated randomized total of 186 participants could be exceeded as participants already enrolled into the Run-In Phase become eligible for the Randomized Trial Phase.
797 798 799 800	The study will be discussed with the child's parent(s) or guardian(s) (referred to subsequently as parent(s)). Parents who express an interest in the study will be given a copy of the informed consent form to read. Written informed consent / assent must be obtained from the parent and child prior to performing any study-specific procedures that are not part of routine care.
801 802 803 804	2.2 Eligibility Criteria for Enrollment into Run-in Phase The following criteria must be met for the child to be enrolled into the study:
805	Inclusion Criteria
806	• Age 5 years to <13 years at time of enrollment. Children within 4 weeks of their 13 th
807 808	birthday are not eligible.Refractive error meeting the following by cycloplegic <i>autorefraction:</i>
809	• Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes
810	• Astigmatism <=1.50D in both eyes
811	 Anisometropia <1.00D SE
812	• Currently wearing refractive correction (single vision eyeglasses or contact lenses)
813	• Excellent compliance with refractive correction (more than 75% of all waking hours) for
814	at least one month, based on investigator judgment after discussion with parent.
815	• Gestational age \geq 32 weeks.
816	• Birth weight >1500g.
817	• Parent understands the protocol and is willing to accept randomization to atropine or
818	placebo.
819	• Is willing to participate in a 2 to 4 week run-in phase using daily artificial tear eyedrops.
820	• Able to return in 2 to 4 weeks for possible randomization.
821 822	• Parent has a phone (or access to phone) and is willing to be contacted by Investigator's site staff.
823	 Relocation outside of the area of an active PEDIG site within next 32 months is not
823	anticipated.
825	
826	Exclusion Criteria

827 828	•	Current or previous myopia treatment with atropine, pirenzepine or other anti-muscarinic agent.
829	•	Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact
830		lenses.
831	٠	Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used
832		to reduce myopia progression.
833	•	Known atropine allergy.
834	•	Abnormality of the cornea, lens, central retina, iris or ciliary body.
835	•	Current or prior history of manifest strabismus, amblyopia, or nystagmus.
836	•	Prior eyelid, strabismus, intraocular, or refractive surgery.
837	•	Down syndrome or cerebral palsy.
838	•	Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple
839	-	sclerosis, Grave's disease, myasthenia gravis, diabetes mellitus, Parkinson's disease)
840	•	Existing ocular conditions (e.g., retinal disease, cataracts, ptosis) or
841	•	systemic/neurodevelopmental conditions (e.g., Down syndrome) which may influence
842		refractive development.
843	•	Any condition that in the judgement of the investigator could potentially influence
844	•	refractive development.
845	•	Existing conditions that may affect the long-term health of the eye or require regular
846	•	pharmacologic treatment that may adversely interact with study medication (e.g., JIA,
847		glaucoma, diabetes mellitus, pre-diabetes)
848	•	Inability to comprehend and/or perform any study-related clinical tests
849	•	Females who are pregnant, lactating, or intending to become pregnant within the next 30
850	•	months.
850		 A negative urine pregnancy test will be required for all females who have
852		experienced menarche.
853		experienced menarche.
854	2.3	Historical Information
855		cal information elicited will include the following: date of birth, sex, race, ethnicity,
856		refractive correction, iris color (brown or not brown), parental history of myopia (0, 1, or
857		its), current medication use, history of and current medical conditions, and myopia
858	-	ent history.
859	ti outility	
860	2.4	Testing at the Enrollment/Run-in Visit
861		g at the enrollment visit/run-in visit will include the following:
862	1 0000002	
863	1	Standard Refraction
	1.	
864		• The investigator may use his/her standard refraction technique (with or without avalantagic) at any time during the visit to ansure that the participant mosts clicibility.
865		cycloplegia) at any time during the visit to ensure that the participant meets eligibility
866	-	criteria with respect to refractive correction as described in section 2.5.
867	2.	Cycloplegic Autorefraction
868		• 1% cyclopentolate – one drop twice to each eye with 5 minutes between drops. The
869		use of proparacaine prior to the cycloplegic drops is at investigator discretion.
870		• Three measurements of sphere, cylinder, and axis will be obtained for each eye using
871		autorefraction (see manual of procedures). Each measurement will be converted to a
872		spherical equivalent refractive error (SER) and the mean of the 3 SER values for each
873		eye will be used for confirming eligibility.

874 875	• A specific autorefractor model is not required for the study; however, each participant should have their autorefraction assessed using the same instrument during the entire
876 877 878 879	 study. The cycloplegic autorefraction should occur at 30 minutes ± 5 minutes from the time the second drop of 1% cyclopentolate was instilled. If eyes are not sufficiently dilated/cyclopleged and/or if the dilation/cycloplegia has
880 881 882 883	worn off before all cycloplegic procedures have been performed, another drop of 1% cyclopentolate may be administered, followed by an additional 30-minute wait before testing. The use of proparacaine prior to this cycloplegic drop is at investigator discretion.
884 885	3. <u>Axial Length Measurement and Additional Biometry</u>
886	• One summary reading based on multiple measures with cycloplegia using optical biometry will be documented for the following (see procedures manual):
887	 Axial length
888	 Flat corneal radius
889	Anterior Chamber depth
890	• Lens thickness, if available
891	• A specific instrument is not required for the study; however, each participant should
892	have axial length and additional biometry assessments made using the same
893	instrument during the entire study.
894	• If eyes are not sufficiently dilated and/or if the dilation has worn off before all
895	cycloplegic procedures have been performed, see procedure for re-dilation in step #2.
896	
807	2.5 Bafractive Correction
897 898	2.5 Refractive Correction To be eligible for randomization, the participant must be wearing refractive correction in each
898	To be eligible for randomization, the participant must be wearing refractive correction in each
	To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary
898 899	To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria:
898 899 900	To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria:
898 899 900 901 902 903	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the
898 899 900 901 902 903 904	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction.
 898 899 900 901 902 903 904 905 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's
 898 899 900 901 902 903 904 905 906 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the
 898 899 900 901 902 903 904 905 906 907 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D.
 898 899 900 901 902 903 904 905 906 907 908 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an over-
 898 899 900 901 902 903 904 905 906 907 908 909 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D.
 898 899 900 901 902 903 904 905 906 907 908 909 910 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an overrefraction or without refractive correction.
 898 899 900 901 902 903 904 905 906 907 908 909 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an over-
 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an overrefraction or without refractive correction. If the participant meets all eligibility criteria for the run-in phase (see section 2.2) but their current correction does not meet the requirements for randomization, then a change in refractive correction can be prescribed in order to meet the requirements when the participant returns for
 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an overrefraction or without refractive correction. If the participant meets all eligibility criteria for the run-in phase (see section 2.2) but their current correction does not meet the requirements for randomization, then a change in refractive correction can be prescribed in order to meet the requirements when the participant returns for potential randomization. A change in refractive correction can also be prescribed if the
 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an overrefraction or without refractive correction. If the participant meets all eligibility criteria for the run-in phase (see section 2.2) but their current correction does not meet the requirements for randomization, then a change in refractive correction can be prescribed in order to meet the requirements when the participant returns for potential randomization. A change in refractive error, but the resulting prescription
 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an overrefraction or without refractive correction. If the participant meets all eligibility criteria for the run-in phase (see section 2.2) but their current correction does not meet the requirements for randomization, then a change in refractive correction can be prescribed in order to meet the requirements when the participant returns for potential randomization. A change in refractive error, but the resulting prescription must meet the criteria above. The prescribed correction can be single vision eyeglasses or
 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an overrefraction or without refractive correction. If the participant meets all eligibility criteria for the run-in phase (see section 2.2) but their current correction does not meet the requirements for randomization, then a change in refractive correction can be prescribed in order to meet the requirements when the participant returns for potential randomization. A change in refractive error, but the resulting prescription must meet the criteria above. The prescribed correction can be single vision eyeglasses or contact lenses. Single vision lenses will be paid for by the study; contact lenses will be at the
 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 	 To be eligible for randomization, the participant must be wearing refractive correction in each eye (single vision eyeglasses or soft, daily wear single vision contact lenses with any necessary adjustment for contact lens rotation and vertex distance) that meets the following criteria: Myopia (by spherical equivalent) in both eyes must be corrected to within ±0.50 D the investigator's cycloplegic measurement of refractive error. Cylinder power in both eyes must be within ±0.50 D of the investigator's standard refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. Cylinder axis for both eyes must be within ±5 degrees of the axis found on the investigator's standard refraction when cylinder power is >= 1.00 D or within ±15 degrees when the cylinder power is <1.00 D. Measurement of refractive error for assessing the above criteria may be performed as an overrefraction or without refractive correction. If the participant meets all eligibility criteria for the run-in phase (see section 2.2) but their current correction does not meet the requirements for randomization, then a change in refractive correction can be prescribed in order to meet the requirements when the participant returns for potential randomization. A change in refractive error, but the resulting prescription must meet the criteria above. The prescribed correction can be single vision eyeglasses or

920 **2.6 Treatment in Run-In Phase**

Artificial tears will be dispensed in single-use ampules to be used 1 drop to each eye nightly in
each eye for 2-4 weeks. Study personnel will demonstrate for the parent and participant how to
instill a drop in each eye prior to the participant leaving the office.

924

927

925 The following will be done to promote compliance with artificial tears during the run-in phase:
926 • A calendar log will be provided to the parent on which the participant or parent will

- A calendar log will be provided to the parent on which the participant or parent will record whether or not the installation was done each night.
- The parent and participant will be instructed to bring all unused ampules of artificial tears with them when they return in 2-4 weeks.
 - A smart phone application may be offered to participants and/or parents who provide consent to be contacted with a nightly prompt asking if the eyedrops were given.
- 931 932

- 933 Participants will be encouraged to wear refractive correction for all waking hours. The calendar
- log used to record artificial tears treatment will also be used to indicate whether refractive
- 935 correction was worn each day.

936	
937 938	Chapter 3: RANDOMIZATION
938 939 940 941 942 943	The participant should return to assess eligibility for randomization within 2-4 weeks after using nightly artificial tears wearing the optical correction prescribed at the enrollment visit. If the participant is unable to return for possible randomization within 6 weeks of enrollment into the run-in, the participant will be withdrawn from the study.
944 945 946 947	3.1 Assessment of Compliance with Artificial Tears Calendar logs will be reviewed to assess the level of compliance with artificial tears eyedrops during the run-in phase. The number of unused artificial tears eyedrop ampules will be counted.
948 949 950 951 952 953 954	To be eligible for randomization, participants must have used artificial tear eyedrops in both eyes for at least 2 weeks and must have been at least 90% compliant with instilling the drops in both eyes (days compliant/total days since receiving study medication as evident by review of the compliance calendar and count of unused ampules) in the run-in phase. Participants not able to return both the unused ampules of artificial tears eyedrops and the calendar log, and participants returning the log who are not compliant at least 90% will be withdrawn from the study.
955 956 957 958 959	In addition, the parent (or participant) must demonstrate the ability to instill an eyedrop in both eyes on their own prior to being considered for randomization. Participants who can't demonstrate successful instillation of eyedrops (either by themselves or by their parent) will be withdrawn from the study.
960 961 962 963 964 965 966	3.2 Assessment of Compliance with Refractive Correction Calendar logs will be reviewed to assess the level of compliance with refractive correction during the run-in phase. Compliance with refractive correction will be classified as excellent (76% to 100% waking hours), good (51% to 75%), fair (26% to 50%), or poor (0 to 25%) based on investigator judgment after review of the compliance calendar and discussion with parent. Participants with excellent (greater than 75% compliance) will be eligible for randomization. Participants 75% compliant or less will be withdrawn from the study.
967 968 969 970 971	3.3 Testing at the Randomization Visit Participants judged to be compliant with eyedrops and refractive correction will have the following assessed:
972 973 974	 Eye Drop Questionnaire To be completed by the child prior to any other testing to evaluate effect of eye drops on the child
975 976 977 978	 2. <u>Distance Visual Acuity Testing</u>: Monocular distance visual acuity testing tested at the start of the exam without cycloplegia in current correction meeting the requirements in section 2.5. Measurement of best corrected visual acuity in each eye by a study certified visual
979	acuity tester using the E-ETDRS testing protocol.
980 981 982	3. <u>Binocular Near Visual Acuity Testing</u> : Binocular near visual acuity is measured using the ATS4 Near Acuity Test with the participant wearing current refractive correction and prior to administration of cycloplegia.

984 accommodation near-point rule (e.g. Gulden's near-point rule) and the participant in their 985 current spectacle or contact lens correction. 986 987 Cycloplegic autorefraction, axial length and additional biometric assessments (following the 988 same procedure as described for enrollment in section 2.4) must be repeated if the enrollment 989 visit was completed more than 4 weeks (>28 days) prior to randomization. If repeated, these will 990 be considered the participant's "baseline" measurements; otherwise the measurements from the 991 enrollment/run-in phase visit will be considered the "baseline" measurements. 992 993 3.4 **Confirmation of Eligibility for Randomization** 994 Visual acuity testing to assess eligibility for randomization must be performed in the 995 participant's current refractive correction. 996 997 Randomization will occur at the conclusion of the randomization exam after confirming that the 998 participant meets the following eligibility criteria: 999 1000 • Best-corrected distance visual acuity in current correction meeting the following criteria: 1001 \circ 20/32 or better in each eye (>=76 letters by E-ETDRS testing) • Interocular difference $\leq 0.2 \log MAR$ (≤ 10 letters by E-ETDRS testing) 1002 1003 1004 • Refractive error meeting the following by cycloplegic *autorefraction (only if repeated on* 1005 day of randomization): 1006 • Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes \circ Astigmatism <=1.50D in both eyes 1007 1008 • Anisometropia <1.00D SE 1009 1010 • Refractive correction that is being worn for each eye (single vision eyeglasses or contact 1011 lenses with any necessary adjustment for contact lens rotation and vertex distance) must 1012 meet the following criteria: • Myopia (by spherical equivalent) in both eyes must be corrected to within ± 0.50 1013 1014 D of the investigator's cycloplegic measurement of refractive error. 1015 \circ Cylinder power in both eyes must be within ± 0.50 D of the investigator's standard 1016 refraction technique, which can be based on a cycloplegic or non-cycloplegic refraction. 1017 1018 • Cylinder axis for both eyes must be within ± 5 degrees of the axis found on the investigator's refraction when cylinder power is ≥ 1.00 D or within ± 15 degrees 1019 when the cylinder power is <1.00 D. 1020 Measurement of refractive error for assessing the above criteria may be performed as an 1021 1022 over-refraction or without refractive correction. • Compliant with artificial tears eyedrops during run-in phase (see definition in section 3.1) 1023 1024 Compliant with refractive correction during run-in phase (see definition in section 3.2). • 1025 1026 Participants who do not meet eligibility criteria will be withdrawn from the study without being 1027 randomized. 1028 1029 Prior to randomization, the study requirements should again be discussed with the parent so that 1030 site staff have reasonable assurance that the participant will be adherent to the protocol.

4. Binocular Amplitude of Accommodation: Measured with a study-specified and provided

1032 **3.5 Randomization**

Eligible participants will be randomly assigned 2:1 to the atropine (0.01%) or placebo group (administering one drop nightly for 24 months), respectively, using a permuted block design stratified by iris color (brown vs non-brown) and by site. The number of participants randomized who self-report as East Asian ethnicity will be limited to no more than 25% of the

- 1037 overall sample (n=47 participants).
- 1038

1039 A participant is officially enrolled in the randomized trial when the website randomization1040 process is completed.

1041

Once a participant is randomized, that participant will be included in the analysis regardless of whether the assigned treatment is received or not. Participants will remain in the study for 30 months of follow-up. Thus, the investigator must not randomize a participant until he/she is convinced that the parent/participant remains willing to participate and will accept either of the

- treatment regimens and complete follow-up as previously discussed at enrollment.
- 1047

1048 Treatment must commence within 1 week following randomization; therefore, a participant 1049 should not be randomized until both the investigator and parent are ready to start treatment.

1050

1051 The participant, parents, coordinators, testers and investigators will be masked to treatment

- 1052 group. If the need arises, the investigator may become unmasked after discussion of a specific
- 1053 case with the protocol chair in response to any adverse events.
- 1054

Chapter 4: TREATMENT AND FOLLOW-UP IN RANDOMIZED TRIAL

1057 4.1 Study Medication

1058 Nevakar is manufacturing the study drug (0.01% atropine) and placebo and packaging both in 1059 identical-appearing single-use ampules. In addition to 0.01% atropine, the ampules contain a 1060 buffer similar to artificial tears while the placebo contains just the buffer similar to artificial 1061 tears. The atropine and placebo ampules are sent to a central pharmacy, which will label and 1062 package multiple atropine or placebo ampules into three month supply packages to maintain 1063 masking. The packages of ampules will be shipped to participating sites in insulated shipping 1064 boxes designed to maintain study drug at 59 to 77 degrees F during shipping. Participating sites 1065 will store study drug at room temperature (between 68 and 77 degrees F) prior to dispensing 1066 study medication packages to study participants. Additional study medication details are 1067 summarized within a separate investigational product manual. 1068

1069 4.2 Treatment 0 to 24 Months

Treatment with study medication will be one drop in both eyes each night, including the night
before study visits. Participants who are wearing contact lenses will be instructed to remove
contact lenses before administering eyedrops and wait at least 30 minutes after eyedrop
administration before reinserting contact lenses.

1074

1075 During the first 24 months of the study, no myopia progression prevention treatment other than
1076 the study eyedrops is permitted.
1077

4.3 Telephone Calls

1079 Two weeks following randomization (± 3 days), the site will contact parents to question the 1080 parent as to whether the child is experiencing any issues with treatment.

1081

1082 At three months following randomization ($\pm \underline{1}$ month), the site will contact parents to encourage 1083 compliance and question the parent as to whether the child is experiencing any issues with 1084 treatment.

1085

1086 The site coordinator will make phone calls in between office visits at 9, 15, 21, and 27 months 1087 following randomization (± 1 month). These calls will be conducted to maintain direct contact 1088 with the parents of each participant, to develop and maintain rapport with the participant and/or 1089 family, and to assist with the scheduling of study visits if needed.

1000

10914.4Masking of Treatment Group

1092 Cycloplegic autorefraction, axial length, and additional biometry will be measured by a masked 1093 examiner at all follow-up visits using the same instrumentation on the participant throughout the 1094 study. Masking will be accomplished by having site personnel administer cyclopentolate to both 1095 eyes of each participant and wait 30 minutes before he/she sees the masked examiner. The 1096 masked examiner may be a technician or an investigator and must be certified to complete these 1097 measurements.

1097

1099 4.5 Compliance with Study Treatment

1100 Unused study medication ampules will be brought to all visits while on randomized treatment

- and will be counted as a measure of treatment compliance.
- 1102

- 1103 To promote compliance with eyedrops, a calendar will be provided on which the child/parent
- 1104 will record the treatment received each day. At each visit, an assessment of compliance will be
- recorded on the Follow-up Examination Form after review of the calendars and an interview with
- 1106 the parent and child.
- 1107

1120

- 1108 If a participant is noncompliant with study eyedrops, the parents and participants should be 1109 encouraged to persist with their efforts to treat to the best of their ability.
- 1111 4.6 Off-Treatment Phase >24 to 30 Months
- 1112 At the 24-month visit, study eyedrops will be discontinued and no myopia treatment other than 1113 optical correction should be prescribed prior to the 30-month visit.
- 1114

11154.7Side Effects of Treatment

Reporting of adverse events is described in Chapter 6. In cases of vision-related adverse events,
distance visual acuity should be measured using the E-ETDRS testing protocol (see section 4.8).
Prior to deviating from the treatment protocol or prescribing non-protocol treatment, the situation
should be discussed with the Protocol Chair.

1121 **4.8 Follow-up Visit Schedule in Randomized Trial**

1122 The follow-up visit schedule consists of the following office visits timed from randomization:

- 1123 6 months ± 2 weeks*
- 1124 12 months ± 2 weeks*
- 1125 18 months \pm 2 weeks*
- 1126 24 months \pm 4 weeks: On-Treatment Primary Outcome discontinue treatment after visit
 - 30 months ± 4 weeks: Off-Treatment Secondary Outcome six months following discontinuation of treatment
- 1128 1129

1127

*A virtual visit may be completed at 6, 12, or 18-months if an in-person office visit cannot be
completed by the participant. If any safety events are identified during a virtual visit, participants will
have additional follow up as applicable.

1133

Additional visits may be scheduled at investigator discretion. Adverse event data may be reportedand collected at any time during the study.

1136

1137 4.9 Follow-up Visit Testing Procedures

1138 At each office visit the following tests and assessments will be done with the participant wearing 1139 their current refractive correction:

- 1140
- Medical History including questioning about the occurrence of adverse effects of treatment.
 Concomitant medications will be recorded, as well as current eyeglasses or contact lenses
 correction.
- 1144 2. <u>Compliance Assessment</u>
- All unused study medication ampules since the last visit (if brought to the visit) will
 be counted as a measure of compliance.
- Home calendar logs (if brought to the visit) will be reviewed and assessments of compliance with eyedrops and with refractive correction will be recorded on the Follow-up Examination Form

1150	3.	Eye Drop Questionnaire (all follow up visits except the 30-month visit)	
1151		• To be completed by the child prior to any other testing to evaluate the effect of	eye
1152		drops on the child.	•
1153	4.	Distance Visual Acuity Testing (30-month visit only): Monocular distance visual acuity	у
1154		tested at the start of the exam without cycloplegia in current correction.	
1155		• Measurement of best corrected visual acuity in each eye by a study certified visual	ual
1156		acuity tester using the E-ETDRS testing protocol.	
1157		• If the vision is more than one line (>=5 letters) worse than baseline, retest using	trial
1158		frames or phoropter with the most recent subjective refraction.	
1159	5.	Binocular Near Visual Acuity Testing (6-month visit only): Binocular near visual acuit	y is
1160		measured using the ATS4 Near Acuity Test with participant wearing current refractive	
1161		correction prior to administration of cycloplegia.	
1162	6.	Binocular Amplitude of Accommodation: Measured in their current correction without	
1163		cycloplegia with a study-specified and provided accommodation near-point rule (e.g.	
1164		Gulden's near-point rule).	
1165	7.	Standard Refraction	
1166		• The investigator may use their standard refraction technique (with or without	
1167		cycloplegia) at any time during the visit to ensure that refractive correction mee	ts
1168		study criteria at each visit (see section 4.9 below).	
1169		• At 30-month visit, only required if the vision is more than one line (>=5 letters)	
1170		worse than baseline.	
1171	8.	Following cycloplegia, at all visits an examiner masked to treatment group will perform	<u>1:</u>
1172		• Cycloplegic Autorefraction – (see section 2.4)	
1173		<u>Cycloplegic Axial Length Measurement and Additional Biometry (see section 2</u>	<u>2.4)</u>
1174	*0		
1175		a virtual visit is completed, only items 1 through 3 above will be completed. If any safety	events
1176 1177	are	e identified during a virtual visit, participants will have additional follow up as applicable.	
1177	In	addition, females who have experienced menarche will undergo a urine pregnancy test a	t each
1179		llow up visit except the 30-month visit (or at home if a virtual visit is completed).	t caom
1180	101		
1181		• In the case of pregnancy during the study, study eyedrops will be discontinued although the study of the st	ough
1182		the subject will be retained in the study.	C
1183			
1184	4.1	10 Management of Refractive Error	
1185	-	ectacle or contact lenses correction must be updated whenever the investigator's standar	
1186		fraction technique reveals a change in refractive error. A change in refractive error is def	ined
1187	as	any of the following amounts:	
1188			
1189		• A difference of ≥ 0.75 D sphere	
1190		• A difference of $\geq 0.75D$ cylinder	
1191		 A difference of ≥0.50D in SE anisometropia A difference in series of C have a series of the series 1.00D 	
1192		• A difference in axis of 6 degrees or more when the cylinder is ≥ 1.00 D.	
1193 1194	W /1	bether to undete the correction for smaller differences in refraction is at investigator disc	rotion
1194		hether to update the correction for smaller differences in refraction is at investigator disc asses required by a contact lens user should be updated when their contact lenses are upd	
1196		d these glasses will be paid for by the study.	accu,
		6	
	M	TS1 Protocol V5.1 (06Apr2020) 4-3	

- 1197
- 1198 If updated, the refractive correction must meet the requirements described in section 2.5.
- 1199
- 1200 Daily wear single vision contact lenses may be used for correction of refractive error full time or
- alternating with spectacle correction. Contact lenses should not differ from a cycloplegic over-
- refraction by more than +/- 0.50D SE. Uncorrected astigmatism should not exceed 1.00D.
- 1203 OrthoK, rigid gas permeable, and other contact lenses being used to affect myopia progression
- are not allowed. Contacts must be removed from the eyes prior to study medication
- administration and not reinserted for at least 30 minutes.
- 1206

1207 4.11 Non-Randomized Treatment Other than Refractive Correction

Non-randomized treatment for myopia other than changes in refractive error as described above
is not permitted during the study. The investigator must call the protocol chair to discuss the
case and obtain approval for an exception prior to initiating non-randomized treatment (including

- 1210 Case and obtain approval for an exception prior to initiating non-randomized treatment (includ 1211 OrthoK, rigid gas permeable, and other contact lenses being prescribed to affect myopia
- 1212 progression).
- 1213

1214 4.12 General Considerations

- 1215 The study is being conducted in compliance with the policies described in the study policies
- document, with the ethical principles that have their origin in the Declaration of Helsinki, with
- 1217 the protocol described herein, and with the standards of Good Clinical Practice.
- 1218
- 1219 There is no restriction on the number of participants to be enrolled by each site towards the
- 1220 overall recruitment goal.
- 1221

1223 1224

Chapter 5: MISCELLANEOUS CONSIDERATIONS IN FOLLOW-UP

1225 5.1 Participant Withdrawals

Parents may withdraw their child from the study at any time. If the parents indicate that they want to withdraw their child from the study, the investigator should attempt to speak with the parents personally to determine the reason. If their interest is in transferring the child's care to another eye care provider, every effort should be made to comply with this and at the same time try to keep the participant in the study under the new provider's care.

1231

1232 **5.2 Discontinuation of Study**

1233 The study may be discontinued by the Steering Committee (with approval of the Data and Safety 1234 Monitoring Committee) prior to the pre-planned completion of enrollment and follow-up for all 1235 participants.

1236

1237 5.3 Travel Reimbursement

1238 The parent of each participant will be compensated \$50 (by merchandise/money card or check)

- 1239 upon completion of the enrollment exam, the randomization exam, and each study visit at 6, 12,
- 1240 18, 24, and 30 months following randomization, for a maximum of \$350. If there are
- extenuating circumstances and/or the participant is unable to complete study visits without additional funds due to travel costs, additional funds may be provided.
- 1243

1250 1251

1252

1253 1254

1255

1244 **5.4 Costs Covered by the Study**

The study will pay for the office visits that are part of the study (enrollment, randomization visit, and visits at 6, 12, 18, 24, and 30 months). The study will pay for virtual visits. Any other visits that are part of routine care will be the parent(s) or their insurance company's responsibility.

1249 The study will pay for the following:

- Study eyedrops (artificial tears, atropine and placebo) will be provided to the participants at no cost.
- Eyeglasses will be provided at enrollment (if needed), and at 12 and 24-month visits if obtained from a study optician.
- Lens changes will be provided at 6 and 18-month visits if a change is required (see Section 4.10) and the lenses are obtained from a study optician.
- The study will pay for bifocals (progressive-addition lenses) if prescribed by the
 investigator because of difficulties seeing up close when doing schoolwork or reading.
- 1258

1259 5.5 Costs Not Covered by the Study

1260 The study will not pay for eyeglasses obtained from a non-study optician. The study will not pay 1261 for contact lenses.

1263 1264	Chapter 6: ADVERSE EVENTS AND RISKS
1264 1265 1266 1267	The study will be performed under an Investigation New Drug Application to the FDA of the US. Specific reporting requirements for adverse events are summarized below.
1207 1268 1269 1270 1271 1272 1273 1274 1275	6.1 Recording of Adverse Events The participant and parent will be queried as to whether or not they have experienced ocular side effects of treatment including lid/conjunctival irritation, light sensitivity, or near blur and/or reading difficulty; as well as any systemic side effects of treatment presenting within one hour following administration of atropine, including dry skin/mouth, tachycardia, fever, flushing, irritability, mental confusion, constipation, aggravation of asthma, or seizures. In addition, all serious adverse events will be recorded.
1276 1277 1278	The study investigator will assess the relationship of each adverse event to be <i>related</i> or <i>unrelated</i> by deciding if there is a reasonable possibility that the adverse event may have been caused by the treatment.
1279 1280 1281 1282	To ensure consistency of adverse event causality assessments, investigators should apply the following general guideline when determining whether an adverse event is related:
1283 1284 1285 1286 1287 1288	Yes There is a plausible temporal relationship between the onset of the adverse event and administration of the study treatment and the adverse event cannot be readily explained by the participant's clinical state, intercurrent illness, or concomitant therapies; and/or the adverse event follows a known pattern of response to the study treatment.
1289 1290 1291 1292 1293	<u>No</u> Evidence exists that the adverse event has an etiology other than the study treatment (e.g., preexisting medical condition, underlying disease, intercurrent illness, or concomitant medication); and/or the adverse event has no plausible temporal relationship to study treatment administration.
1294 1295 1296 1297	The maximum intensity that occurred since the onset of an adverse event will be rated on a three-point scale: (1) mild, (2) moderate, or (3) severe, categorized as follows:
1297 1298 1299 1300 1301	<u>Mild</u> - Symptom(s) barely noticeable to participant or does not make participant uncomfortable; does not influence performance or functioning; prescription drug not ordinarily needed for relief of symptom(s).
1302 1303 1304 1305	<u>Moderate</u> - Symptom(s) of sufficient severity to make participant uncomfortable; performance of daily activity is influenced; participant is able to continue in study; treatment for symptom(s) may be needed.
1306 1307 1308 1309	<u>Severe</u> - Symptom(s) cause severe discomfort; severity may cause cessation of treatment with study medication or device; treatment for symptom(s) may be given and/or participant hospitalized.

- 1310 It is emphasized that the term severe is a measure of intensity: thus, a severe adverse event is not
- 1311 necessarily serious. For example, itching for several days may be rated as severe, but may not be
- 1312 clinically serious.
- 1313
- 1314 Adverse events that continue after the study participant's discontinuation or completion of the
- 1315 study will be followed until their medical outcome is determined or until no further change in the 1316 condition is expected.
- 1317

1321

1322

1323

13186.2Reporting Serious or Unexpected Adverse Events

- 1319 A serious adverse event is any untoward occurrence that:
 - Results in death.
 - Is life-threatening; (a non-life-threatening event which, had it been more severe, might have become life-threatening, is not necessarily considered a serious adverse event).
 - Requires inpatient hospitalization or prolongation of existing hospitalization.
- Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions (sight-threatening).
- Is a congenital anomaly/birth defect.
- Is considered a significant medical event by the investigator based on medical judgment
 (e.g., may jeopardize the participant or may require medical/surgical intervention to
 prevent one of the outcomes listed above).
- 1330
- 1331 Unexpected adverse events are those that are not identified in the current Clinical Investigator's1332 Brochure.
- 1333

1334 Serious or unexpected adverse events must be reported to the Coordinating Center immediately1335 via completion of the online serious adverse event form.

1336

The Coordinating Center will notify all participating investigators of any adverse event that is
both serious and unexpected. Notification will be made within 10 days after the Coordinating
Center becomes aware of the event.

- 1340
- Each principal investigator is responsible for reporting serious study-related adverse events and
 abiding by any other reporting requirements specific to their Institutional Review Board.

13446.3Data and Safety Monitoring Committee Review of Adverse Events

- 1345 A Data and Safety Monitoring Committee will approve the protocol, template informed consent 1346 form, and substantive amendments, and provide independent monitoring of adverse events.
- 1347 Cumulative adverse event data will be tabulated for review by the DSMC at intervals determined
- by the coordinating center and the DSMC. Following each DSMC data review, a summary will
- 1349 be made available for submission to Institutional Review Boards.
- 1350

1351 **6.4 Risks**

1352 6.4.1 Risks of Examination Procedures

1353 The procedures in this study are part of daily eye care practice in the United States and pose no additional risks.

1354 add 1355

1356 6.4.2 Risk of Atropine Therapy

The effects of long-term use of bilateral atropine eye drops when used as treatment for myopia progression depend on the strength of atropine used. Side effects are uncommon with the 0.01% dosage to be used in this protocol, based on a series of 84 participants treated with 0.01% atropine for 2 years (ATOM2). In most cases the events were deemed not related to the treatment. Six children had eye symptoms felt related to the therapy, 1 case of irritation and 1 case of blurred vision in the 0.01% group. Further treatment for two additional years was not associated with side-effects.

1364

A common side effect of atropine 1% is blurry vision, particularly at near, which may cause problems with reading at school and near work. The 0.01% dosage used in this study is not expected to be frequently associated with reading problems or blur at near.

1368

Following atropine administration, local side effects of minimal severity include allergic lid reactions, local irritation, conjunctival hyperemia, and follicular conjunctivitis. In the ATOM2

1371 series, 1% of participants had irritation sufficient to warrant discontinuation of treatment; no

- 1372 cases of allergic conjunctivitis or allergic dermatitis were reported.
- 1373

1374 Potential systemic side effects include dry skin and mouth, tachycardia, fever, flushing and

irritability. These effects were not reported (ATOM2), but rather some more minor complaintssuch as blurring and some light sensitivity with atropine 0.1% and 0.5% in the first two years of

1377 treatment. The only severe adverse event with 0.01% was 1 participant (1%) with acute gastric

- 1378 pain which was not felt to be related to the atropine (ATOM2).
- 1379

1380 Atropine 1% produces dilation of the pupil, which increases the light that enters the eye.

1381 Although it has not been demonstrated that atropine used for 2 years could have harmful ocular

1382 effects, excessive exposure to light theoretically could be toxic to the retina. The strength used

1383 in this study is expected to have minimal effect on pupil dilation.³⁹ If there is light sensitivity,

clip-on or flip-up sunglasses or photochromic lenses will be provided. The use of hats withbrims or visors will be encouraged along with sunglasses.

1385

Participants who experience problems with schoolwork or significant symptoms when reading
may be prescribed progressive bifocals paid for by the study. These will be provided irrespective
of treatment assignment after consultation with the protocol chair.

1390

Atropine in various dosages from 0.01% to 1% has been used long-term to prevent the

1392 progression of myopia without any lasting adverse effect on visual acuity.^{32, 41, 49, 50} In the

1393 ATOM2 trial, the most common side effect in the 0.01% atropine group was loss of one or more

1394 lines of distance visual acuity (13%) but this was reversible upon discontinuing medication.

1395

1396 If a participant develops adverse effects serious enough to discontinue study medication prior to 1397 the 24-month on-treatment primary outcome exam, the Investigator should call the Protocol

1398 Chair to discuss the case. Progressive lenses should be tried for near focusing problems before

1399 stopping therapy. Reading glasses may be prescribed for participants using contact lenses. If

1400 study medication is discontinued, the participant will continue in follow-up.

1401

1402 In the case of pregnancy during the study, study eyedrops will be discontinued although the 1403 subject will be retained in the study.

1404 6.4.3 **Risk Assessment**

- The Jaeb Center Institutional Review Board has classified the protocol as research involving greater than minimal risk using the federal definition under 45 CFR 46.102i. 1405
- 1406

Chapter 7: SAMPLE SIZE ESTIMATION AND STATISTICAL ANALYSIS

1409 The approach to sample size and statistical analyses are summarized below. A detailed statistical 1410 analysis plan will be written and finalized without knowledge of study data. The analysis plan 1411 synopsis in this chapter contains the framework of the anticipated final analysis plan.

1412

1413 7.1 Primary Objective: Efficacy on Atropine Treatment (24 Months)

1414 The primary objective is to determine the efficacy of atropine for slowing progression of myopia 1415 after 24 months of treatment.

1416

1417 7.1.1 Primary Analysis – Refractive Error at 24 Months (On-Treatment)

The primary analysis will be a treatment group comparison of change from baseline to 24months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction, using a longitudinal discrete time mixed model, which allows for interaction between time and treatment group, and adjusts for baseline SER, age, iris color (brown vs. non-brown) and East Asian vs. non-East Asian race, to account for potential residual

1423 confounding and improve power for the treatment comparison. At baseline and all follow-up

- visits, including the 24-month visit, the mean of the three readings from autorefraction in each eve will be calculated and then the mean of both eves for each participant will be used for the
- eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. If fewer than 3 readings are available in each eye, the mean of available readings will
- 1427 be used for each eye to obtain the mean of both eyes for each participant. The baseline SER will
- be included in the analysis model as an adjustment factor, while the change in SER at all follow-
- 1429 up visits up to and including the 24-month visit will be included in the longitudinal outcome
- 1430 vector. Further details, including handling of missing data, will be included in the Statistical1431 Analysis Plan.
- 1431 1432
- 1433 The treatment group difference (atropine placebo) and a 95% confidence interval will be
- 1434 calculated based on the model estimates at 24 months.
- 1435

The primary analysis will follow the intention-to-treat principle. All randomized participants will
be analyzed according to their randomized treatment group regardless of whether/what treatment
was received, including non-randomized treatment for myopia (section 4.109).

1439

1440 7.1.1.1 Sensitivity Analyses

As a sensitivity analysis, the primary analysis will be repeated using an analysis of covariance model (ANCOVA) model in which SER at 24 months is adjusted for SER at baseline. Multiple imputation with the Monte Carlo Markov Chain (MCMC) method will be used to impute missing change in SER for participants who missed the 24-month visit or did not complete cycloplegic autorefraction testing at the 24-month visit. In addition, change in SER will also be imputed for participants who start non-randomized treatment.

1447

1448**7.1.2**Secondary Outcomes at 24 Months (On-Treatment)

- Each secondary analysis below will be conducted using the same approaches as defined above for the primary analysis unless otherwise specified.
- 1451

1452 7.1.2.1 Proportion of Participants with Progression >=2D at 24 Months

1453 The relative risk of progression of myopia SER $\geq 2D$ from baseline between participants in the 1454 atropine group and the placebo group will be estimated using a Cox proportional hazards model,

- 1455 which adjusts for baseline SER, age, iris color (brown vs. non-brown) and East Asian vs. non-
- 1456 East Asian race. An alternative analysis method will be used if the proportional hazards 1457 assumption is not met.
- 1457 1458

1459 7.1.2.2 Change in Axial Length at 12 and 24 Months

- 1460 Axial length will be reported as the distributions of baseline length, 12-month length, 24-month
- 1461 length, and change in axial length from baseline to 12 and 24 months. A treatment group
- 1462 comparison of the change from baseline to 12 months and 24 months in axial length will be 1463 performed using a longitudinal discrete time mixed model, which allows for interaction between
- 1464 time and treatment group, and adjusts for baseline axial length, age, iris color (brown vs. non-
- brown) and East Asian vs. non-East Asian race. At baseline and all follow-up visits, including
- 1466 the 12 and 24-month visits, the mean of the axial length readings in both eyes for each
- 1467 participant will be used for the analysis. The treatment group difference (atropine placebo) and
- a 95% confidence interval will be calculated based on the model estimates at 12 months and 24months.
- 1470

1471 **7.1.2.3 Compliance**

- 1472 Compliance with study medication will be assessed at the 6-month, 12-month, 18-month, and 24-
- 1473 outcome exams. For each of these exams, the distribution of number of calendar days that study
- 1474 medication was reported used and the distribution of the number of unused study medication
- ampules will be compared between treatment groups.
- 1476

1477 Compliance with refractive correction will be assessed at every follow up visit. After discussion

- 1478 with the parent and child, study personnel will classify the proportion of time refractive error was
- 1479 worn will be described as excellent (76% to 100%), good (51% to 75%), fair (26% to 50%), or
- 1480 poor ($\leq 25\%$). The distribution of refractive correction compliance will be compared between
- 1481 treatment groups.1482

1483**7.1.3**Secondary Outcomes at 12 Months (On-Treatment)

- 1484 Each secondary analysis below will be conducted using the same approaches as defined above 1485 for the primary analysis unless otherwise specified.
- 1486 1487 **7.1.3.1 Refractive Error at 12 Months**
- The model used for the primary analysis at 24 months will also be used to perform a treatment group comparison of change from baseline to 12-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction.
- 1491

1492 7.1.3.2 Proportion of Participants with Progression >=1D at 12 Months

- The relative risk of progression of myopia SER >= 1D from baseline between participants in the atropine group and the placebo group will be estimated using a Cox proportional hazards model, adjusting for baseline SER, age, iris color (brown vs. non-brown) and East Asian vs. non-East Asian race. An alternative analysis method will be used if the proportional hazards assumption is
- 1497 not met.

1498

1499 7.2 Secondary Objective: Efficacy off Atropine Treatment (30 Months)

- 1500 The secondary objective of the study is to determine the efficacy of atropine treatment for
- 1501 slowing progression of myopia after a period of 6 months off treatment. All analyses as
- 1502 described in section 7.1 above will be repeated using data from the 30-month off-treatment visit.

- 1503
- 1504 7.3 Additional Analyses
- 1505 7.3.1 Treatment Effect in Subgroups
- 1506 The treatment difference for spherical equivalent refractive error (SER) change from baseline to 1507 24 and 30 months within the following subgroups will be explored:
- 1508 Baseline SER
- Brown iris versus non-brown iris
- 1510 Race/ethnicity
- 1511 Baseline age
 - Baseline age and baseline SER
- 1514 These planned subgroup analyses will repeat the primary analysis, including the baseline factor 1515 and the baseline factor by treatment interaction. In general, statistical power will be low for 1516 detection of interactions unless the interaction is very large.
- 1517

- 1518 Subgroup analyses will be interpreted with caution, particularly if the corresponding overall
- analysis does not demonstrate a significant treatment group difference.
- 1520

1521 7.3.2 Treatment Effect over Time

- 1522 The treatment effect on change in spherical equivalent refractive error (SER) from baseline 1523 through the first year will be compared with the treatment effect on change in SER from end of 1524 first year through the second year, by constructing the appropriate contrasts in the primary 1525 analysis model.
- 1526

1527 7.3.3 Exploratory Analyses of Additional Ocular Biometric Parameters

- As exploratory analyses at 24 and 30 months, change in flat corneal radius, anterior chamber depth, and lens thickness will each be compared between treatment groups at 24 and 30 months using a longitudinal discrete time mixed model which allows for interaction between time and treatment group, and adjusts for the baseline value of the parameter, age, iris color (brown vs. non-brown), and East Asian vs. non-East Asian race.
- 1533

1534 7.4 Safety Analyses

1535

1536 7.4.1 Adverse Effects of Eye Drops

- An eyedrops questionnaire will be administered at randomization and at each follow-up visit except the 30-month visit. The distribution of scores on each survey item will be summarized by treatment group at the time of randomization and at each follow-up exam up until and including the 24-month visit. The average of the item responses at the 24-month visit will be calculated
- and compared with a t-test for difference in means between treatment groups.
- 1542

1543 **7.4.2 Visual Acuity**

- 1544 The proportion of participants with loss of best corrected distance vision >1 logMAR line at 30 1545 months in either eye will be compared between treatment groups using Barnard's test. The
- 1546 proportion of participants with loss of best corrected near binocular vision >1 logMAR line at 6
- 1547 months will be compared between treatment groups using Barnard's test.
- 1548

1549 **7.5 Need for Bifocals**

- 1550 The proportion of participants needing bifocals in both groups will be evaluated.
- 1551

1552 7.6 Interim Analysis

As specified by the DSMC, the decision of whether an interim analysis will be conducted will be evaluated after 6 months of recruitment and before any outcome data is reviewed. An interim monitoring plan will be developed at that point if circumstances warrant.

1556

1559

1561

1557 7.7 Data Tabulations and Other Analyses

1558 The following tabulations will be performed according to treatment group:

- Baseline demographics and clinical characteristics
- A flow chart accounting for all participants for all visits and phone calls
 - Visit and phone contact completion rates for each follow-up visit
 - Protocol deviations
- 1562 1563

1564 **7.8 Sample Size**

1565 7.8.1 General Considerations

The goal of this section is to summarize data from prior studies of myopia progression, use these data to formulate assumptions about the expected treatment effect and its standard deviation, and to calculate the sample size needed to provide at least 90% power for each of the 2 hypothesis tests corresponding to the 24-month on treatment (primary) and 30-month off-treatment secondary objectives.

1571

1572 To collect more safety data from participants using atropine, sample size was based on a 2:1 1573 allocation (2 participants will be randomized to the atropine group for every 1 participant

1574 randomized to the placebo group).

1575

1576 **7.8.2** Sample Size for Primary Objective: Efficacy on Atropine Treatment

1577

1578 Comparison of SER at 24 months

Sample size calculations for the on-treatment comparison of refractive error at 24 months were
based upon data from the CLEERE group and ATOM1 for untreated participants meeting similar
eligibility criteria, and data from participants treated with atropine 0.01% in the ATOM2 study.^{28,}
^{31,51} The participants in these studies were 6 to <13 years old with refractive error of -1.00D to -
6.00D spherical equivalent and astigmatism of -1.50D or less. The ATOM1 and ATOM2 studies
were conducted in Asian populations whereas the race/ethnicity of participants in the CLEERE
study was more reflective of the US population.

1586 1587

1588

- In 404 untreated participants from CLEERE (N=214) and ATOM1 (N=190), the mean progression after 24 months was 1.12D (95% CI = 1.05 to 1.18D) with standard deviation (SD) of 0.69D (95% CI = 0.65 to 0.75D).
- 1589 1590 1591
- In 75 participants treated with 0.01% atropine from ATOM2, the mean progression after 24 months was 0.49D (95% CI = 0.35 to 0.63D) with SD of 0.60D (95% CI = 0.52 to 0.72).
- 1593 1594

- 1595 The on-treatment effect after 24 months in our study is estimated to be 0.50D based on a
- 1596 conservative estimate of 1.00D 24-month progression in untreated participants and an estimated
- 1597 0.50D 24-month progression in participants treated with 0.01% atropine.
- 1598
- 1599 Assuming a conservative standard deviation of 0.80D (based on CLEERE), and using a 2-sided
- 1600 t-test with alpha = 0.05, a sample size of 123 participants (82 in the atropine group and 41 in the
- 1601 placebo group) is needed to detect a difference in mean change in SER (atropine placebo) at 24
- 1602 months with 90% power, assuming the true mean difference is 0.50D or larger (Table 1).
- 1603 Since the correlation between baseline refractive error and change in refractive error at 24
- 1604 months in the CLEERE data was low (r=0.05), no reduction in sample size was taken to account
- 1605 for the correlation between baseline and the outcome at 24 or 30 months. Accounting for up to 100% loss to follow we even 24 months the second size for d^{12} which is 128 months is 128 months.
- 1606 10% loss to follow-up over 24 months, the sample size *for this objective* is 138 participants 1607 overall (92 in the atropine group and 46 in the placebo group).
- 1608

1609 Table 1: Total Sample Size Estimates for Various Treatment Group Differences in Mean 1610 SER Score at 24 Months or 30 Months*

Standard Deviation Mean SER Change from Baseline to	True Treatment Group Difference (D) in Mean SER Change between Baseline and 24 Months or 30 Months						
24 Months or 30 Months(D)	0.40 0.50		0.60	0.625			
0.60	111 (74:37)	72 (144:72)	51 (34:17)	48 (32:16)			
0.70	147 (98:49)	96 (64:32)	69 (46:23)	63 (42:21)			
0.80	192 (128:64)	123 (82:41)	87 (58:29)	81 (54:27)			
0.90	243 (162:81)	156 (104:52)	111 (74:37)	102 (68:34)			
1.00	300 (200:100)	192 (128:64)	135 (90:45)	123 (82:41)			

1611 Cells indicate total sample size needed assuming a 2:1 randomization. (Numbers in parenthesis reflect number

- 1612 needed in each group atropine:placebo).
- 1613 *Sample sizes based on a t-test to evaluate a difference between treatment groups in mean change from baseline at 1614 24-months, with a 2-sided alpha=0.05, and power=90%.
- 1615

1616 **7.8.3 Sample Size for Secondary Objective: Efficacy off Atropine Treatment**

1617

1618 **Comparison of SER at 30 months**

- 1619 In CLEERE, the mean progression after 36 months was 1.50D in 127 untreated participants
- 1620 (95% CI = 1.34 to 1.66 D) with a SD of 0.89D (95% CI = 0.79 to 1.02 D). If the rate of
- 1621 progression in our study is similar (approximately 0.25D every 6 months), then the progression
- 1622 rate between baseline and 30-months in placebo participants is estimated to be 1.25D.
- 1623
- 1624 In ATOM2, the 71 participants who stopped atropine at 24 months progressed a mean of 0.28D 1625 (SD = 0.33D) after 12 months off treatment (95% CI for mean change = 0.20 to 0.36 D); and 1626 their mean progression from baseline to 36 months was 0.72D (95% CI = 0.55 to 0.89 D) with 1627 SD of 0.72D (95% CI = 0.62 to 0.86 D).
- 1628

If atropine group participants progress at the same rate as ATOM2 participants between 24 and 30 months

- 1631 If atropine participants progress at the same rate as ATOM2 participants between 24 and 30
- 1632 months (estimated to be about 0.125 D over six months), then the estimated progression rate

- 1633 between baseline and 30-months in the atropine group is 0.625D (0.50D at 24 months plus
- 1634 0.125D between 24 and 30 months). Compared with the estimated 1.25D progression rate in the
- 1635 placebo group between baseline and 30-months (based on CLEERE data), the treatment group
- 1636 difference would be expected to be 0.625D in favor of the atropine group.
- 1637
- Assuming a slightly larger standard deviation of 0.90D at 30-months, and using a 2-sided t-test
- 1639 with alpha = 0.05, a sample size of 102 participants (68 in the atropine group and 34 in the
- 1640 placebo group) is needed to detect a mean difference in SER (atropine placebo) at 30 months
- 1641 with 90% power, if the magnitude of the true mean difference is 0.625D or larger (Table 1). 1642 Accounting for up to 15% loss to follow-up over 30 months, the sample size *for this objective* is
- Accounting for up to 15% loss to follow-up over 30 months, the sample size *for this objective* is 1643 120 participants overall (80 in the atropine group and 40 in the placebo group) under this
- 1643 120 participants overall (80 in the atropine group and 40 in the placebo group) under this 1644 scenario.
- 1645

If atropine group participants progress at the same rate as placebo participants in CLEERE between 24 and 30 months

- 1648 If atropine participants progress at the same rate as placebo participants in CLEERE (i.e. no
- 1649 treatment effect) between 24 and 30 months (0.25D), then the estimated progression rate
- between baseline and 30-months in the atropine group is 0.75D (0.50D at 24 months plus 0.25D
- between 24 and 30 months). Compared with the estimated 1.25D progression rate in the placebo
- 1652 group between baseline and 30-months (based on CLEERE data), the treatment group difference
- 1653 would be expected to be 0.50D in favor of the atropine group.
- 1654

Assuming a slightly larger standard deviation of 0.90D at 30-months, and using a 2-sided t-test

- 1656 with alpha = 0.05, a sample size of 156 participants (104 in the atropine group and 52 in the
- 1657 placebo group) is needed to detect a mean difference in SER (atropine placebo) at 30 months
- 1658 with 90% power, if the magnitude of the true mean difference is 0.50D or larger (Table 1).
- Accounting for up to 15% loss to follow-up over 30 months, the sample size *for this objective* is
- 1660 186 participants overall (124 in the atropine group and 62 in the placebo group) under this 1661 scenario.
- 1662

1663 7.8.4 Summary of Sample Size Estimation

- To be conservative, sample size for the study was chosen based upon the comparison of SER at 30 months (secondary objective) assuming that atropine group participants will progress at the same rate as placebo between 24 and 30 months and that expected treatment group difference between baseline and 30 months will be 0.50D, the scenario which has the largest sample size requirement.
- 1668
- 1670 The total sample size for the study will be 186 participants (124 in the atropine group and 62 in 1671 the placebo group).
- 1672

1673 7.8.5 Precision within Racial Subgroups

- 1674 Table 2 below summarizes the expected ¹/₂-width of a 2-sided 95% confidence interval on the
- 1675 treatment group difference of myopia progression for the exploratory analysis within subgroups 1676 defined by race/ethnicity with an overall sample size of 156 participants completing the 30-
- 1677 month primary outcome exam.
- 1678
- For example: if participants of East Asian race/ethnicity make up 25% of the total sample (26 inatropine group and 13 in placebo group) and the standard deviation of progression in this group

- 1681 is 0.80D, then the expected width of 2-sided 95% confidence interval for the treatment group
- difference in East Asians is $\pm 0.55D$. 1682
- 1683

1684 Table 2. Expected width of 2-sided 95% confidence interval on the treatment group

1685 comparison of myopia progression as a function of the standard deviation of progression 1686 and sample size per race/ethnicity subgroup*

Race/Ethnicity	Standard Deviation of							
Subgroup as	Mean SER Change from Baseline** (D)							
Proportion of Total Sample Size	0.8	0.9	1.0	1.1	1.2	1.3	1.4	
10% n=15	±0.95	±1.06	±1.18	±1.30	±1.42	±1.54	±1.66	
20% n=30	±0.63	±0.71	±0.79	±0.87	±0.95	±1.03	±1.11	
25% n=39	±0.55	±0.62	±0.69	±0.76	±0.83	±0.89	±0.96	
30% n=48	±0.49	±0.55	±0.62	±0.68	±0.74	±0.80	±0.86	
40% n=63	±0.43	±0.48	±0.53	±0.59	±0.64	±0.69	±0.75	
50% n=78	±0.38	±0.43	±0.48	±0.53	±0.57	±0.62	±0.67	
60% n=93	±0.35	±0.39	±0.44	±0.48	±0.52	±0.57	±0.61	
70% n=108	±0.32	±0.36	±0.40	±0.45	±0.49	±0.53	±0.57	
80% n=126	±0.30	±0.34	±0.37	±0.41	±0.45	±0.49	±0.52	
90% n=141	±0.28	±0.32	±0.35	±0.39	±0.42	±0.46	±0.49	

1687 1688

*Cells show the expected ½-width of 2-sided 95% confidence interval on the treatment group comparison of myopia 1689 progression as a function of the standard deviation of progression and sample size per race/ethnicity subgroup. 1690

1691 **The range of standard deviation was based on the standard deviation of progression in CLEERE group data at 36-1692 months, stratified by race/ethnicity group. At 36 months, the standard deviations of progression in Asian, Black, 1693 Hispanic, and White populations were 1.02D (95% CI =0.82 to 1.36D), 0.61D (95% CI =0.47 to 0.88D), 0.82D

1694 (95% CI =0.67 to 1.05D), and 0.92D (95% CI =0.70 to 1.36D) respectively.

1696 Chapter 8: DATA COLLECTION AND MONITORING

1698 8.1 Case Report Forms and Device Data

1699 The main study data are collected through electronic case report forms (CRFs). These electronic 1700 CRFs from the study website are considered the primary source documentation.

1701 When data are directly collected in electronic case report forms, this will be considered the

1702 source data. Each participating site will maintain appropriate medical and research records for

this trial, in compliance with ICH E6 and regulatory and institutional requirements for theprotection of confidentiality of participants.

1705

1697

1706 8.2 Study Records Retention

1707 Study documents will be retained for a minimum of 3 years following the submission of the final 1708 financial report for the last grant cycle for which the study is conducted or 2 years following the 1709 date a marketing application is approved for the drug for the indication for which it is being 1710 investigated; or if not approved, 2 years after the IND is withdrawn, whichever is later. No

records will be destroyed without the written consent of the sponsor. It is the responsibility of

1712 the sponsor to inform the investigators when study documents no longer need to be retained.

17131714 8.3 Quality Assurance and Monitoring

Designated personnel from the Coordinating Center will be responsible for maintaining quality
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is
conducted and data are generated, documented and reported in compliance with the protocol,
Good Clinical Practice (GCP) and the applicable regulatory requirements. Adverse events will
be prioritized for monitoring.

1720

1721 A risk-based monitoring (RBM) plan will be developed and revised as needed during the course

1722 of the study, consistent with the FDA "Guidance for Industry Oversight of Clinical

1723 Investigations — A Risk-Based Approach to Monitoring" (August 2013). Study conduct and

monitoring will conform with 21 Code of Federal Regulations (CFR) 812.

1725

The data of most importance for monitoring at the site are participant eligibility and adverse
events. Therefore, the RBM plan will focus on these areas. As much as possible, remote
monitoring will be performed in real-time with on-site monitoring performed to evaluate the

1729 verity and completeness of the key site data. Elements of the RBM may include:

- Qualification assessment, training, and certification for sites and site personnel
- Oversight of Institutional Review Board (IRB) coverage and informed consent procedures
- Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol
 review of entered data and edits, statistical monitoring, study closeout
- On-site monitoring (site visits): source data verification, site visit report
- Communications with site staff
- Patient retention and visit completion
- Quality control reports

- Management of noncompliance
- Documenting monitoring activities
- Adverse event reporting and monitoring

1742 Coordinating Center representatives or their designees may visit the study facilities at any time in

order to maintain current and personal knowledge of the study through review of the records,
comparison with source documents, observation and discussion of the conduct and progress of
the study.

1745 the 1746

1747 **8.4 Protocol Deviations**

A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure
requirements. The noncompliance may be either on the part of the participant, the investigator,
or the study site staff. As a result of deviations, corrective actions are to be developed by the site
and implemented promptly.

1752

1753 The site PI/study staff is responsible for knowing and adhering to their IRB requirements.

1754 Further details about the handling of protocol deviations will be included in the monitoring plan.

1755

Chapter 9: ETHICS/PROTECTION OF HUMAN PARTICIPANTS

1759 9.1 Ethical Standard

The investigator will ensure that this study is conducted in full conformity with Regulations for
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50,
21 CFR Part 56, and/or the ICH E6.

1764 9.2 Institutional Review Boards

The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent/assent forms must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study. All changes to the consent and/or assent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re-consented.

1771

1772 9.3 Informed Consent Process

1773 9.3.1 Consent Procedures and Documentation

1774 Informed consent (and assent if required) is a process that is initiated prior to the parent and child 1775 agreeing to participate in the study and continues throughout the individual's study participation. 1776 Extensive discussion of risks and possible benefits of participation will be provided to the 1777 participants and their families. Consent forms and assent forms if required will be IRB-approved 1778 and the parent and child if required will be asked to read and review the document. The 1779 investigator will explain the research study to the parent and child and answer any questions that may arise. All parent(s) will receive a verbal explanation in terms suited to their comprehension 1780 1781 of the purposes, procedures, and potential risks of the study and of their child's rights as research 1782 participants. Parent(s) will have the opportunity to carefully review the written consent form and 1783 ask questions prior to signing.

1784

The parent(s) and child should have the opportunity to discuss the study with their surrogates or
think about it prior to agreeing to participate. The parent will sign the informed consent
document prior to any procedures being done specifically for the study. The participants may
withdraw consent at any time throughout the course of the trial. A copy of the informed consent
document will be given to the participants for their records. The rights and welfare of the
participants will be protected by emphasizing to them that the quality of their medical care will
not be adversely affected if they decline to participate in this study.

1792

1793 9.3.2 Participant and Data Confidentiality

Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the sponsor(s) and their agents. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.

1799

1800 The study monitor, other authorized representatives of the Jaeb Center for Health Research, or

1801 representatives of the IRB may inspect all documents and records required to be maintained by

1802 the investigator, including but not limited to, medical records (office, clinic, or hospital) and

- 1803 pharmacy records for the participants in this study. The clinical study site will permit access to
- 1804 such records.

- 1805 The study participant's contact information will be securely stored at each clinical site for
- 1806 internal use during the study. At the end of the study, all records will continue to be kept in a
- 1807 secure location for as long a period as dictated by local IRB and Institutional regulations.
- 1808 Study participant research data, which is for purposes of statistical analysis and scientific
- 1809 reporting, will be transmitted to and stored at the Jaeb Center for Health Research. Individual
- 1810 participants and their research data will be identified by a unique study identification number.
- 1811
- 1812 The study data entry and study management systems used by clinical sites and by the Jaeb Center
- 1813 for Health Research Coordinating Center research staff will be secured and password protected.
- 1814 At the end of the study, all study databases will be de-identified and archived at the Jaeb Center
- 1815 for Health Research and made available to the public.
- 1816

1817		Chapter 10: REFERENCES
1818		
1819	1.	Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and risk factors for myopia.
1820		Ophthalmic & Physiological Optics 2012;32(1):3-16.
1821	2.	Eye Diseases Prevalence Research Group. The prevalence of refractive errors among
1822		adults in the United States, Western Europe, and Australia. Archives of Ophthalmology
1823		2004;122(4):495-505.
1824	3.	Foster PJ, Jiang Y. Epidemiology of myopia. Eye (Lond) 2014;28(2):202-8.
1825	4.	French AN, Morgan IG, Burlutsky G, et al. Prevalence and 5- to 6-year incidence and
1826		progression of myopia and hyperopia in Australian schoolchildren. Ophthalmology
1827		2013;120(7):1482-91.
1828	5.	Giordano L, Friedman DS, Repka MX, et al. Prevalence of refractive error among
1829		preschool children in an urban population: the Baltimore Pediatric Eye Disease Study.
1830	6	Ophthalmology 2009;116(4):739-46.
1831	6.	Multi-Ethnic Pediatric Eye Disease Study Group. Prevalence of myopia, hyperopia, and
1832		astigmatism in non-Hispanic white and Asian children: multi-ethnic pediatric eye disease
1833	7	study. Ophthalmology 2013;120(10):2109-16.
1834	7.	Multi-Ethnic Pediatric Eye Disease Study Group. Prevalence of myopia and hyperopia in 6- to 72-month-old african american and Hispanic children: the multi-ethnic pediatric eye
1835 1836		disease study. Ophthalmology 2010;117(1):140-7.
1830	8.	Vitale S, Sperduto RD, Ferris FL, 3rd. Increased prevalence of myopia in the United
1838	0.	States between 1971-1972 and 1999-2004. Archives of Ophthalmology
1839		2009;127(12):1632-9.
1840	9.	Xiang F, He M, Morgan IG. The impact of parental myopia on myopia in Chinese
1841	۶.	children: population-based evidence. Optometry and Vision Science 2012;89(10):1487-
1842		96.
1843	10.	Lam CS, Edwards M, Millodot M, Goh WS. A 2-year longitudinal study of myopia
1844		progression and optical component changes among Hong Kong schoolchildren.
1845		Optometry and Vision Science 1999;76(6):370-80.
1846	11.	Fan DS, Lam DS, Lam RF, et al. Prevalence, incidence, and progression of myopia of
1847		school children in Hong Kong. Investigative Ophthalmology & Visual Science
1848		2004;45(4):1071-5.
1849	12.	Edwards MH, Li RW, Lam CS, et al. The Hong Kong progressive lens myopia control
1850		study: study design and main findings. Investigative Ophthalmology & Visual Science
1851		2002;43(9):2852-8.
1852	13.	Grodum K, Heijl A, Bengtsson B. Refractive error and glaucoma. Acta Ophthalmologica
1853		Scandinavica 2001;79(6):560-6.
1854	14.	Tano Y. Pathologic myopia: where are we now? American Journal of Ophthalmology
1855	15	2002;134(5):645-60.
1856	15.	Willis JR, Vitale S, Morse L, et al. The Prevalence of Myopic Choroidal
1857 1858		Neovascularization in the United States: Analysis of the IRIS((R)) Data Registry and NHANES. Ophthalmology 2016;123(8):1771-82
1858 1859	16.	NHANES. Ophthalmology 2016;123(8):1771-82. Walline JJ, Lindsley K, Vedula SS, et al. Interventions to slow progression of myopia in
1859	10.	children. Cochrane Database of Systematic Reviews 2011(12):CD004916.
1860	17.	Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia
1862	1/.	Control in Children: A Network Meta-analysis. Ophthalmology 2016;123(4):697-708.
1002		control in canaron. At room one from analysis. Ophilannology 2010,125(4).097-700.

1863 Sherwin JC, Reacher MH, Keogh RH, et al. The association between time spent outdoors 18. 1864 and myopia in children and adolescents: a systematic review and meta-analysis. 1865 Ophthalmology 2012;119(10):2141-51. 1866 19. Sherwin JC, Hewitt AW, Coroneo MT, et al. The association between time spent 1867 outdoors and myopia using a novel biomarker of outdoor light exposure. Investigative 1868 Ophthalmology & Visual Science 2012;53(8):4363-70. 1869 20. Guo Y, Liu LJ, Xu L, et al. Outdoor activity and myopia among primary students in rural 1870 and urban regions of Beijing. Ophthalmology 2013;120(2):277-83. 1871 21. Derby H. On the atropine treatment of acquired and progressive myopia. Transactions of 1872 the American Ophthalmological Society 1874;2:139-54. 1873 22. Cooper J, Schulman E, Jamal N. Current status on the development and treatment of 1874 myopia. Optometry 2012;83(5):179-99. 1875 23. Prepas SB. Light, literacy and the absence of ultraviolet radiation in the development of 1876 myopia. Medical Hypotheses 2008;70(3):635-7. 1877 24. Wollensak G, Iomdina E, Dittert DD, et al. Cross-linking of scleral collagen in the rabbit 1878 using riboflavin and UVA. Acta Ophthalmologica Scandinavica 2005;83(4):477-82. 1879 25. Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and 1880 cyclopentolate on myopia. Annals of Ophthalmology 1989;21(5):180-1822, 187. 1881 26. Shih YF, Chen CH, Chou AC, et al. Effects of different concentrations of atropine on controlling myopia in myopic children. Journal of Ocular Pharmacology and 1882 1883 Therapeutics 1999;15(1):85-90. Shih YF, Hsiao CK, Chen CJ, et al. An intervention trial on efficacy of atropine and 1884 27. 1885 multi-focal glasses in controlling myopic progression. Acta Ophthalmologica 1886 Scandinavica 2001;79(3):233-6. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood 1887 28. myopia. Ophthalmology 2006;113(12):2285-91. 1888 1889 29. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: 1890 safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of 1891 Myopia 2). Ophthalmology 2012;119(2):347-54. 30. 1892 Loh KL, Lu Q, Tan D, Chia A. Risk factors for progressive myopia in the Atropine 1893 Therapy for Myopia Study. American Journal of Ophthalmology 2015;159(5):945-9. 1894 31. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 1895 2: Myopia Control with Atropine 0.01% Evedrops. Ophthalmology 2016;123(2):391-9. 1896 Brodstein RS, Brodstein DE, Olson RJ, et al. The treatment of myopia with atropine and 32. 1897 bifocals: a long-term prospective study. Ophthalmology 1984;91:1373-9. 1898 33. Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: 1899 effect on myopia progression after cessation of atropine. Ophthalmology 2009;116(3):572-9. 1900 1901 34. Chia A, Chua WH, Wen L, et al. Atropine for the treatment of childhood myopia: 1902 changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 1903 2014;157(2):451-7 e1. 1904 35. Chen KK, Poth EJ. Racial differences as illustrated by the mydriatic action of cocaine, 1905 euphthalmine, and ephedrine. The Journal of Pharmacology and Experimental 1906 Therapeutics 1929;36:429-45. 1907 36. Emiru VP. Response to mydriatics in the African. British Journal of Ophthalmology 1908 1971:55(8):538-43. 1909 Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. Journal of 37. 1910 Pharmacology and Experimental Therapeutics 1976;197(1):79-88.

1911 Li SM, Wu SS, Kang MT, et al. Atropine slows myopia progression more in Asian than 38. 1912 white children by meta-analysis. Optometry and Vision Science 2014;91(3):342-50. 1913 Cooper J, Eisenberg N, Schulman E, Wang FM. Maximum atropine dose without clinical 39. 1914 signs or symptoms. Optometry and Vision Science 2013;90(12):1467-72. 1915 40. Loughman J, Flitcroft DI. The acceptability and visual impact of 0.01% atropine in a 1916 Caucasian population. Br J Ophthalmol 2016. 1917 41. Kennedy RH, Dyer JA, Kennedy MA, et al. Reducing the progression of myopia with 1918 atropine: a long term cohort study of Olmsted County students. Binocular Vision & 1919 Strabismus Quarterly 2000;15:281-304. 1920 Wu PC, Yang YH, Fang PC. The long-term results of using low-concentration atropine 42. 1921 eye drops for controlling myopia progression in schoolchildren. Journal of Ocular 1922 Pharmacology and Therapeutics 2011;27(5):461-6. 1923 43. Lee JJ, Fang PC, Yang IH, et al. Prevention of myopia progression with 0.05% atropine 1924 solution. J Ocul Pharmacol Ther 2006;22(1):41-6. 1925 44. Fang PC, Chung MY, Yu HJ, Wu PC. Prevention of myopia onset with 0.025% atropine 1926 in premyopic children. J Ocul Pharmacol Ther 2010;26(4):341-5. 1927 45. Tideman JW, Snabel MC, Tedja MS, et al. Association of Axial Length With Risk of 1928 Uncorrectable Visual Impairment for Europeans With Myopia. JAMA Ophthalmol 1929 2016;134(12):1355-63. 1930 46. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in 1931 myopia aetiology. Prog Retin Eye Res 2012;31(6):622-60. Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in 1932 47. 1933 an older population. Ophthalmology 2002;109(4):704-11. 1934 Bedrossian RH. The effect of atropine on myopia. Ophthalmology 1979;86(5):713-9. 48. 1935 Chiang MF, Kouzis A, Pointer RW, Repka MX. Treatment of childhood myopia with 50. 1936 atropine eyedrops and bifocal spectacles. Binocular Vision & Strabismus Quarterly 1937 2001;16(3):209-15. 1938 Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) 51. 1939 Study Group. Unpublished data provided through personal communications with PEDIG. 1940 2016. 1941